<SEC-DOCUMENT>0001628280-21-003278.txt : 20210225
<SEC-HEADER>0001628280-21-003278.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225160210
ACCESSION NUMBER:		0001628280-21-003278
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210225
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		21680163

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf8-k022521.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id7a8f5d932364fc7b038fc8760ccfff6_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt"><font><br></font></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;8-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">February 25, 2021</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="cardiff_logoxrgbxtm1a.jpg" src="cardiff_logoxrgbxtm1a.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:146px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Cardiff Oncology,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">001-35558</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27-2004382</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11055 Flintkote Avenue</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">San Diego, CA 92121</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(858) 952-7570</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CRDF&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 2.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Results of Operations and Financial Conditions.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On February 25, 2021, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the fourth quarter and full year ended December 31, 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="a991crdf022521.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Press Release of Cardiff Oncology, Inc. dated February 2</a><a href="a991crdf022521.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5</a><a href="a991crdf022521.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">, 2021</a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> February 25, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991crdf022521.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id709d6524a3442d7a8ad4bac45f72ba2_1"></div><div style="min-height:72pt;width:100%"><div><img alt="cardiff_logoxrgbxtm1a.jpg" src="cardiff_logoxrgbxtm1a.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:115%">Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:115%"> </font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SAN DIEGO (February 25, 2021) &#8211; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc. (Nasdaq&#58; CRDF)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, </font><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Over the last several months we achieved key clinical milestones, which provided the momentum for our successful raise of over $100 million. Together, these events have enabled us to accelerate the execution of our clinical programs and expand our pipeline to other relevant cancer indications,&#8221; said Dr. Mark Erlander, chief executive officer of Cardiff Oncology. &#8220;Data from our lead KRAS-mutated metastatic colorectal cancer (mCRC) program show promising and durable efficacy, highlighting the potential of onvansertib in combination with standard-of-care FOLFIRI (irinotecan and 5-FU)&#47;bevacizumab to address the need for a new second-line treatment option. Importantly, we completed enrollment in the Phase 1b portion of this trial in December of 2020 and initiated patient accrual in the Phase 2 segment in January of this year. Based on the mCRC trial results, we are leveraging the known synergy of onvansertib with irinotecan and 5-FU by evaluating this combination (nanoliposoamal irinotecan and 5-FU) in pancreatic ductal adenocarcinoma (PDAC). Approximately 95% of PDAC patients have a KRAS mutation and current second-line treatment for this indication conveys only a 7.7% response rate and 6-month median overall survival benefit. We plan to initiate a Phase 2 trial in this indication in the first half of the year following the receipt of our &#8220;study may proceed&#8221; notification from the FDA last month. Our goal is to further demonstrate the broad applicability of onvansertib across KRAS-mutated cancers and to address an indication with a significant unmet need for new treatment options.&#8221;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dr. Erlander continued, &#8220;Onvansertib&#8217;s broad applicability extends beyond targeting KRAS-mutated cancers, as shown by the exciting progress of our metastatic castrate-resistant prostate cancer (mCRPC) trial. The addition of onvansertib to daily abiraterone treatment in patients showing initial resistance to abiraterone has resulted in durable disease control. Notably, the most recent data presented at ASCO-GU showed a significant increase in disease control rate in patients receiving onvansertib for more days within a treatment cycle. Looking ahead, the progress we&#8217;ve made across our clinical programs leaves us poised to achieve a steady cadence of catalysts throughout 2021 and beyond as we continue to advance onvansertib&#8217;s development.&#8221;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Program highlights for the quarter ended December 31, 2020 include&#58; </font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Milestones&#58;</font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Raised gross proceeds of approximately $100 million in an offering of common stock</font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cardiff Oncology substantially strengthened its balance sheet in the fourth quarter, closing an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $13.50 per share, before deducting underwriter discounts and commissions and estimated offering expenses. The underwriters also exercised an option to purchase an additional 975,000 shares at the public offering price (less the underwriting discounts and commissions). The Company intends to use the net proceeds </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">from this offering for clinical development of onvansertib, working capital and for other general corporate purposes. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Appointed Dr. Rodney Markin as Chairman of the Board</font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prior to being appointed Chairman, Dr. Markin previously served as a Director on Cardiff&#8217;s Board from February 2014 to December 2020. He has extensive medical expertise and experience in institutional healthcare, and is currently the Vice President for Network Development, Nebraska Medicine and Associate Vice Chancellor for Business and Executive Director of the UNeTech Institute at the University of Nebraska Medical Center. In addition to currently holding several other distinguished positions in academia, Dr. Markin also has served on the boards of Perceptimed Inc. since 2014, MikroScan Technologies Inc. since 2015, Afaxys Inc. since 2017 and Paradigm Diagnostics Inc. since 2018.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Program&#58;</font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Identified a biomarker associated with onvansertib-abiraterone synergy that is enriched in mCRPC patients with the clinically defined basal molecular tumor subtype</font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Collaborative studies with the Massachusetts Institute of Technology and Decipher Biosciences identified a gene signature (biomarker) related to cell division pathways that can be used to predict which cancer cells will show a synergistic anti-tumor response to treatment with onvansertib in combination with abiraterone. This gene signature is correlated with the clinically defined basal molecular subtype of mCRPC, suggesting that patients with this tumor subtype may be more likely to respond to onvansertib-abiraterone combination therapy. These studies were featured in an electronic poster at the 27</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Annual Prostate Cancer Foundation Scientific Retreat.</font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Acute Myeloid Leukemia (AML) Program&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Presented data at ASH demonstrating the safety and anti-leukemic activity of onvansertib in relapsed&#47;refractory AML</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Updated data from a Phase 1b&#47;2 clinical trial evaluating onvansertib in combination with decitabine in relapsed&#47;refractory AML patients were featured in a virtual oral poster presentation at the 62</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> American Society of Hematology (ASH) Annual Meeting. These data demonstrated the safety, tolerability and anti-leukemic activity of the onvansertib-decitabine combination and showed an over-representation of splicing factor mutations in patients achieving a complete response. Additional highlights from the presentation included&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">9 of 45 (20%) evaluated patients achieved a complete remission with or without hematologic count recovery (CR&#47;CRi - 5 in Phase 1b and 4 in Phase 2)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">55% of responders had a mutation in a splicing factor</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">2 patients proceeded to transplant following CR and 3 patients had ongoing responses as of the ASH data cutoff</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">4 patients have achieved a durable response (&#8805;9 months) &#8211; as of data cut-off date</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Decreases in mutant circulating tumor DNA (ctDNA) within the first treatment cycle appeared to be highly correlated with clinical response&#59; 7 of 7 (100%) patients with CR&#47;CRi showed a decrease </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in mutant ctDNA after one cycle of treatment, while only 2 of 15 (13%) non-responders showed a similar decrease</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Data demonstrated that onvansertib in combination with decitabine is a safe and well-tolerated treatment regimen</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Highlights for the period subsequent to the quarter end include&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">KRAS-mutated Metastatic Colorectal Cancer (mCRC) Program&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Announced updated data from its Phase 1b&#47;2 trial evaluating onvansertib plus FOLFIRI (irinotecan and 5-FU)&#47;bevacizumab in second line KRAS-mutated mCRC patients and initial findings from its Expanded Access Program (EAP)  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In conjunction with the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), Cardiff Oncology announced updated Phase 1b data demonstrating the clinical benefit of onvansertib in KRAS-mutated mCRC, as well as initial findings from its EAP. Data highlights from the Phase 1b trial, as of January 6, 2021, include&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">12 of 14 (86%) evaluable patients achieved a clinical benefit (SD &#8211; stable disease plus PR &#8211; partial response)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">5 of 14 (36%) evaluable patients achieved a PR&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:13.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4 patients had a confirmed PR&#59; 1 patient went on to have curative surgery&#59; 1 patient with a non-confirmed PR went off study following PR due to a treatment-unrelated AE</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">3 patients with SD remain on treatment, including 2 who have yet to have their 16-week (second) scan&#59; time to achieving a PR ranges from 2 to 6 months in trial participants on treatment</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Clinical responses were observed across different KRAS variants, including the 3 most common in colorectal cancer</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Patients achieving a PR or SD showed the greatest decrease in plasma mutant KRAS after one cycle of therapy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The combination of onvansertib and FOLFIRI&#47;bevacizumab was well tolerated</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enrollment of patients in the Phase 1b segment of the trial is complete and the recommended Phase 2 dose of onvansertib has been confirmed at 15 mg&#47;m</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Phase 2 segment of the trial is open to full enrollment of approximately 26 patients across 6 trial sites&#58; USC Norris Comprehensive Cancer Center, Mayo Clinic Cancer Centers (Arizona, Rochester, Jacksonville), Kansas University Medical Center and CARTI Cancer Center.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the EAP, Cardiff Oncology announced that 6 of the initial 9 patients treated showed tumor shrinkage and remained on treatment with durable responses lasting an average of 6 months. Notably, 5 different KRAS mutation subtypes were represented amongst these patients and most patients had received prior treatment with FOLFIRI and progressed before enrolling in the EAP.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Program&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Announced updated Phase 2 data showing a two-fold increase in efficacy with an optimized onvansertib dosing schedule</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Updated data from a Phase 2 trial evaluating the </font><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">all-oral combination of onvansertib, abiraterone and prednisone in patients showing initial abiraterone resistance were featured in a virtual oral poster presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU). These data showed that </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">increasing the number of days of treatment with onvansertib from 5 to 14 in a 21-day cycle was associated with a greater than two-fold increase (29% to 63%) in disease control rate (DCR) at 12 weeks, the trial&#8217;s primary efficacy endpoint. Across all cohorts, the DCR at 12 weeks is 35% (13&#47;37), indicating the trial is on track to meet the stated criteria for success on its primary efficacy endpoint (30% DCR at 12 weeks). Additional highlights from the presentation included&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The optimized dosing schedule of cohort C shows a greater than two-fold improvement in disease control rate compared to cohorts A and B</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt">63% (5&#47;8) of cohort C patients achieved the primary efficacy endpoint compared to 29% (5&#47;17) and 25% (3&#47;12) of cohort A and B patients, respectively </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">75% (6&#47;8) of evaluable patients in cohort C had radiographic stable disease (SD) at 12 weeks, compared to 53% (9&#47;17) in cohort A, 42% (5&#47;12) in cohort B and 54% (20&#47;37) across all cohorts</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">All cohort C patients achieving the primary efficacy endpoint remain on treatment</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Data show that the combination of onvansertib and abiraterone is well tolerated across the three different dosing schedules of cohorts A-C&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt;text-decoration:underline">Cohort A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; 24 mg&#47;m</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> onvansertib on Days 1-5 of 21-day cycles, plus abiraterone and prednisone beginning on Day 1 and continuing uninterrupted throughout each cycle</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt;text-decoration:underline">Cohort B</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; 18 mg&#47;m</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> onvansertib on Days 1-5 of 14-day cycles, plus abiraterone and prednisone beginning on Day 1 and continuing uninterrupted throughout each cycle</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt;text-decoration:underline">Cohort C</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; 12 mg&#47;m</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> onvansertib on Days 1-14 of 21-day cycles, plus abiraterone and prednisone beginning on Day 1 and continuing uninterrupted throughout each cycle</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Program&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Received &#8220;Study May Proceed&#8221; letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 trial of onvansertib in metastatic PDAC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Phase 2 clinical trial of onvansertib in metastatic PDAC is designed to </font><font style="background-color:#ffffff;color:#313133;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</font><font style="color:#313133;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#313133;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), leucovorin and fluorouracil (5-FU) as a second-line treatment in patients with metastatic PDAC who have failed first-line gemcitabine-based therapy. Onvansertib&#8217;s potential in PDAC, where &#126;95% of patients have a KRAS mutation, is supported by the promising clinical data seen in the KRAS-mutated mCRC trial evaluating onvansertib in combination with irinotecan and 5-FU (FOLFIRI). Initiation of the Phase 2 trial is expected in the first half of 2021.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#313133;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Fourth Quarter Financial Results&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of December 31, 2020, Cardiff Oncology had approximately $131 million in cash and cash equivalents.</font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Net cash used in operating activities in the fourth quarter of 2020 was $5.1 million, an increase of $1.8 million from $3.3 million for the same period in 2019.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The increase is attributed mainly to outside services and professional fees, facilities and other and changes in operating assets and liabilities.</font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Research and development expenses increased by approximately $0.3 million to $3.2 million for the three months ended December 31, 2020, from $2.9 million for the same period in 2019. The increase in </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">research and development expenses was primarily due to the increased outside service costs and clinical studies for advancing the development of our drug candidate, onvansertib. We expect increases in research and development costs to continue as we advance the onvansertib clinical development programs.</font></div><div><font><br></font></div><div><font style="background-color:#fefefe;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased by approximately $1.9 million to $3.4 million for the three months ended December 31, 2020, from $1.5 million for the same period in 2019. The increase is primarily due to a one time increase in stock compensation expense, and outside services and professional fees.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Cardiff Oncology, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival.  We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three clinical programs that have demonstrated the safety and efficacy of onvansertib&#58; a Phase 1b&#47;2 study of onvansertib in combination with FOLFIRI&#47;Avastin&#174; (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC)&#59; a Phase 2 study of onvansertib in combination with Zytiga&#174; (abiraterone)&#47;prednisone in metastatic castration-resistant prostate cancer (mCRPC)&#59; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;www.cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates&#59; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; our ability to develop tests, kits and systems and the success of those products&#59; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Cardiff Oncology Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vicki Kelemen</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Operating Officer</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">858-952-7652</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vkelemen&#64;cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LifeSci Advisors</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">212-915-2569</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">jallaire&#64;lifesciadvisors.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Karen O&#8217;Shea, Ph.D.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LifeSci Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">929-469-3860</font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">koshea&#64;lifescicomms.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id709d6524a3442d7a8ad4bac45f72ba2_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except for per share amounts)</font></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br> December 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,865&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,235&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,162&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,761&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,616&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,382&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,452&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,923&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,497)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,289)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,086)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,678)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from change in fair value of derivative financial instruments warrants</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,597)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,242)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,307)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,414)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Stock Dividend</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,290)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,603)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,248)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,597)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,707)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.08)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.80)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,566&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,329&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,875&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,974&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,981&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,195&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,055&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,356&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,354&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,727&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,087&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders' Equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,119&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,782&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments warrants</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,569&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,776&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,158&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,311&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,727&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,087&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,307)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,414)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments - warrants</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(654)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,315)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,268)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of common stock, preferred stock and warrants, net of expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,300&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,818&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs related to the clinical trial funding commitment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,872&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings under note payable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of note payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,313&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,078&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,786&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,258)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents Beginning of period</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,195&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,453&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents End of period</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,981&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,195&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cardiff_logoxrgbxtm1a.jpg
<TEXT>
begin 644 cardiff_logoxrgbxtm1a.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M Q$!_\0 Y@ !  (" @,! 0            H+" D&!P,$!0$" 0$  @(# 0$
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M,5IK?'DK:EZ6CG6U;1%JS'C$Q$ONB7'
M
M
M
M
M
M
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MJQ$1K-Z3?'$<;6K,^6-V Y+P
M
M
M
M
M
M
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M?)Y=)G.06O/
M
M
M
M
M
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M^$R[:&3I
M
M
M
M
M
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MF)XQ+WP5@
M
M
M
M
M
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M:$]\>H_=_J'OOMG<^[OEQUG7'AK[F#%X?S>*)\L3I.DWGS9+1\5Y9ABQ^&
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MS,4K[<^/C;#]-I\V/PC),\&W0<AXD
M
M
M
M
M
M                                                          ,9
MN4_,'CUPQUS(V;R$V'5852'YF*.H[OS#+LRM&FR65+AF+Q35:Y!9*[D]_B03
M$5"O+)=99)3B<+Y*8X\UYTA^M[.[&[G[]ZI'2.V-K?<;CA-[?#CQ5G\?+DGW
M:5]FLZVGA2+6TA"SY^_<+<D.2J+S77&N/9<9]-3D2J^1;5U@T[NS,*UX^PU6
MV70%G'P.-(:0DSAT*TRF^YQMRRDM+["Z[+N[WX4]VO[K?CTU^[%VKVG./JG=
MDTZMUZNEHK:NFTQ6C\G%/'-,?E9O=GA,8J6C5'ID2)$N0_+EOO2I4IYV1)DR
M'5O2)$AY:G'GWWG%*<=>=<4:E*49J4HS,SZCB-G*UK2L4I$12(TB(X1$1RB(
M\(AX09     #8[P:]6/+?GO:Q96J\(7C.JVYY1+W=V>MS*/7=:EEPDSX]-+.
M.Y/S:[BH^APJEF4IIQ392EQFUDZ5N+!DR_#'N^UY9ZA^L79/IMAFG6=Q\[K,
MUUIM,.E\]M>4VC73%2?R\DUUC7R1>8\J;)P%]*_$C@P5/F9T_P#'#?<%"7E[
M@V)60W"H)YH;2XYK;"O).I<&0DT'XY1KG72"<<0=@;*_$798MMCQ<>=O;_ T
M ]2O7WO;U$^9L//_ ./[;MP^S8+3[]?Z?+POF^FNE,4Z1/RO-'F;@!R'AP
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M+;6<=X][%FK'.V+)'NVCC&L<+UUB+UK,Z,J!F_'
M
M
M
M
M
M
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M<*YJ1IYHY7CWZ<-:UV<"YY&
M
M
M
M
M
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M+Y$=U]M=2[.[BW?;/5Z^7?[/--+:<K1SIDKX^3)2:WIKI/EM&L1.L.[QD_/
M
M
M
M
M
M
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M3]@K;7'ML6M-OCX\-*:SY[1^7DF^33AYM.#/ 6O.
M   8/\S/7=Q4YW8NJEWSKJ+*R:'"5"QG:N+_ !L?VEB"34M;::;*D1)*IE>T
MZXI?Y=9,SZM:U&M48UDE159,./+&EHX^WQ>A=A^J'>7ISO/M';>ZM7:6MKDV
M^36^WR_QL>L:6\//CFF33A%]."%=S^]#7*OA]^=9]J^-+Y*:(AG*FN91A-+)
M3L+#:MEHY2W,^UY%783DP8+"7/):U3D^ EIA3\HH!+0R.NR[7)CXUXU;\^FO
MWCNS>^/E]-ZO->D]QVTCY>6\?)RVGA_,YYTC69TTQY(I?6?+3YFDV:+QQFQ
M   "6W]L)RZ?K\HW!PJRJU=56Y%!=W5J5B4\DV8E]4I@4NR,?@^3N>-VZIEU
MUFRPCM:;*KFN].]U1JY^RR<9QS]<?OM*?O==D5R[/8]_;.D?-Q6C:[F8CC-+
M:WP7GP]RWGQS,\9^9CKRK&DR8=@T2
M
M
M
M
M
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M?AP
M
M
M
M
M
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M[[K<VM?<9;VO>TSK-K6F9M:9\9F9F9GVOJ I
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MT1:/&(:C]:Z%UCMW?6Z9US;9=KOJ<ZWKIK'MK/*U9\+5F:SX3+DP[AU(
M
M
M
M
M
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MK
M
M
M
M
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M8HF8K']-3C;%]<^;'KPB\S.C)D>R/)0
M
M
M
M
M
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M4CG;-ACPI'/)CCA6-;4TI$UC9<-QFIH
M
M
M
M
M
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MSKVM/TM0.X.YNN]U;^>I=P;G+N=W.NDVGW:Q/XM*1I2E?S:5B/H<Q'Z!T0
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M#UC[(IV1WEEVVSKY>C;N/GX.'"M;3,7Q1^KO$Q$<XI-)GFR3'L#RD
M
M
M
M
M
M                                           %/\.@?<,  &2'#?\
MPO.*W^4AH[^Z=BXSQ_I*_7'X7Y7OK_1'6?\ U6[_ ,/D6N([Q\9@
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MN'URW!#?UHX
M
M
M
M
M
M "G^'0/N&  #)#AO_A><5O\ *0T=_=.Q<9X_TE?KC\+\KWU_HCK/_JMW_A\B
MUQ'>/C,                              "J_]A7^'WSB_P L#DO_ ':,
MU'29?TMOXT_A?8OTQ_VU[>_]'L/\+B8?"M^X  !;HZ\_Y@8-_8?C/]980[Z.
M4?4^)75/\SW'Z_)_+ES 2X( UT^Q4S_1>N2ZGT/*+4S+^0S*I3T/I_LEU/\
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ML59GG%*WF:QK[*^;RQ[*Q$1PAB:/"GM( RRX2?X1.)?\697_ -&[(>Z_=O\
M]V=A^IW/^'R/%OO _P"U^]_7;?\ KZ-Y0^ECYY
M
M
M
M
M
M                             I_AT#[A@  R0X;_ .%YQ6_RD-'?W3L7
M&>/])7ZX_"_*]]?Z(ZS_ .JW?^'R+7$=X^,P
M      *K_P!A7^'WSB_RP.2_]VC-1TF7]+;^-/X7V+],?]M>WO\ T>P_PN)A
M\*W[@  %NCKS_F!@W]A^,_UEA#OHY1]3XE=4_P SW'Z_)_+ES 2X( UT>Q7_
M )EZY_LGM?ZU(&I/WMO].](_ON7^J;2?=<_S[JO]SQ_UDM30T4;I #Z=)_[Y
MJ/\ C.!_OIH<WIO^8[?]=3^5#B=0_L&?]3?^3*32/LH^2@
M-)/.O_K^L?[&,:_WL\/G!]YK_=++_<MO_)E] ?NZ_P"VN+^^9_Y4,.1KZ]U
M&67"3_")Q+_BS*_^C=D/=?NW_P"[.P_4[G_#Y'BWW@?]K][^NV_]?1O*'TL?
M/(
M
M
M
M
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M'R/%OO _[7[W]=M_Z^C>4/I8^>0
M
M
M
M
M
M                 *?X= ^X8  ,D.&_^%YQ6_RD-'?W3L7&>/\ 25^N/POR
MO?7^B.L_^JW?^'R+7$=X^,P                              *K_ -A7
M^'WSB_RP.2_]VC-1TF7]+;^-/X7V+],?]M>WO_1[#_"XF'PK?N   6Z.O/\
MF!@W]A^,_P!980[Z.4?4^)75/\SW'Z_)_+ES 2X( UT>Q7_F7KG^R>U_K4@:
MD_>V_P!.](_ON7^J;2?=<_S[JO\ <\?]9+4T-%&Z0 ^G2?\ OFH_XS@?[Z:'
M-Z;_ )CM_P!=3^5#B=0_L&?]3?\ DRDTC[*/DH              #23SK_Z_
MK'^QC&O][/#YP?>:_P!TLO\ <MO_ "9?0'[NO^VN+^^9_P"5##D:^O=0!EEP
MD_PB<2_XLRO_ *-V0]U^[?\ [L[#]3N?\/D>+?>!_P!K][^NV_\ 7T;RA]+'
MSR
M
M
M
M
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M (?(\6^\#_M?O?UVW_KZ-Y0^ECYY
M
M
M
M
M
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MG$O^+,K_ .C=D/=?NW_[L[#]3N?\/D>+?>!_VOWOZ[;_ -?1O*'TL?/(
M
M
M
M
M
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MW_[L[#]3N?\ #Y'BWW@?]K][^NV_]?1O*'TL?/(
M
M
M
M
M
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MWF^QUT\9ICBV2T_5%JTB?IM#<X/H<T-
M
M
M
M
M
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MPT[W_3]_TK>9.G]3PY=OO\5O+?'DK:EZ6CPM6T1,3]<.4B7#
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M66\70>@=%[8Z7BZ+T#;8MITO#&E<>.-(X\YF9UFUK3QM>TS:T\;3,\75PAW
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M.9B9B89E#81X0
M
M
M
M
M
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M0B(A]"XB*QY:\(AH?,S,ZSQF7Z)0
M
M
M
M
M
M                    CE>[_P!/KO+NEE<G^-]"R?)C%*J+&S##H9PX2-W8
MC41C9CDRIQ#+;FR\;A-MM0''74_F->T4)1J<:ADGB;G;_,CST^/\/_%M-]WS
MUQCLC<5[0[JR3_\ 4LUYG%EG6?LF2TZSKS_F,DZS>(CW+S\R-(G)K!"M:JTH
MK2RI+NMGT]U3SYE5;U%K#D5]I56E?(<B3ZVR@2VV9<&?!ELK:>9=0EQIQ)I4
M1&1D.KY<)YOHSAS8=SAIN-O>N3;Y*Q:MJS%JVK:-:VK:-8F)B8F)B=)CC#T
M6     #=!P!]X'+/A+^2X-D%BYR!T' .+$3K+8-Q,.\Q6ICM%'3%UIGKC=C:
MXLPPRVVEJOE-6-.TA!I9B,+<6\.1BW.3'PGC3V?P/!?4O[O?9?J!\SJ.VK'3
M.Y+:S]HPUCR9+3QUSX?=KDF9UUO6:99F?>O:(BJ:[PC]FW$SGK1,.Z:SQJLV
M$S".7?Z9S=4.@V=1$RCNEO-TOS),7)JB.1=RI]2_-BH2I).J:<,VT]ECS8\L
M>[/'V>+0+U!]).]/3?<3'7MM-^F3;2FZQ:WV]]>4>?2)QVG\C)%+3Q\L6CBV
M""UYF              # WFG[)>)O W'ESMX[#87FDJ"N9CFH<.*-D>TLF+Q
MN+C+C8VW+CMT=7+4TI*+*W?KJQ2TF@GS<Z(.K)FQXH]Z>/L\7H_8/I3WIZC[
MKY?;VUG[!%M+[G+K3;X_;KDTGSVC7CCQ1?)IQ\NG%"FY_>]+EAS._/<#PF<]
MQVT'8>:$K L$MI!Y?EE6K\!HV'L-IN!:VC,QM2TO5M<BMJW&7/%(9EFCS*Z[
M+N<F3A'"C?STU^[MV7V'\OJ74*QU3N2ND_.S5CY6.W]!@XUK,<-+WF^2)CS5
MM37RQI)'&;      #V8<.98S(E?7Q),^?/DL0X,&&P[*F3)DIU+$:)$C,)6]
M(DR'EI0VVA)J6HR(B,S!CDR4Q4MERVBN.L3,S,Z1$1QF9F>$1$<9F>2=5Z0_
M3>_Q5AU7*_DS3-_WQ.04SA:^U[-:;=+26/W44VY4^Y)7>D]H7E<\;#R$_2FA
MNN1S-4AY]+/9[;;^3^<O\?X/^+YU_>"]=:]Y9+]F=I9)_P#J^+)_/9HG3[7>
MD\(K_P#\]+1K$_\ 5M$6^&M?-).',:I       QCW=Q5UUN8W[=UI6*YJMLB
M3E-/':4<U:")#97]8:F6+E*$$22<[V91)2E)/=B20/&?4CT0[2]0_-O[Q.Q[
MCF.&YQ5CWYCA'S\?"N6(CAYM:9-(B/F>6/*];]/_ %D[I[#\NRI,;SH$3_9\
MMI]S7C/R<G&<6L\=-+8]9F?)YI\S4EMWCOLS34EQ>2TYS<?4Z:(>64Q.S:*0
M2EFEI,AXFTO5<IS_ '*2AM2CZ]AK(NX:']^^DW>7IYFFW6-O\SI4VTINL6M\
M-N.D>:=(G':?R<D5F9^'S1Q;K]D>J':7?F&(Z5G^7U.(UMMLNE<U>''RQKID
MK'Y6.;1'XWEG@Z,'FCT0    (S(R,C,C(^I&7T,C+]AD?\AD'+C',Y\)Y,RM
M,\T]C:V1'ILJ\FP\590EEB/:S5-9#6-I/H@J^^<:DNR8[:3Z$Q+2\1)2E#:V
M4D?787T\^\5W=V?6G3NN:]6Z'6(B*Y+S&?''AY,\Q:;5B/Q,L7X1%:6QQ#PC
MOST#[6[KM;?]&TZ7UFTZS;'77#DGQ\^&)K%;3^7CFO&9M>MYEVKLWV"75M6J
MK=78RO&),ALTR,BR%R)96$7O09&575,I<KFGVU_4GI"Y"3+Z>$CZ*'[?O+[U
M?4=]L_L?96RG99KQ[V?/-<F2NL?]/%&N.)B>5[SDB>7RXGB_&]I?=FV&RW?V
MOO#=QN\59]W!ABV.EM)_ZF2=+S$^-:12?SYC@U[7E]=Y-:2[O(K:PN[><YY)
M=E:2WILQ]7["[WY"UK-*$_1*>O:E)$1$1$1#5'J?5.I=9WN3J75L^7<[_+.M
MLF2TWO:?IM:9G2.41RB.$:0V<Z=TWI_2-G3I_2\.+;[''&E:8ZQ2L?5$1$<>
M<SSF>,\7R1P7-    <OPG <PV+=,X_A=!87]H[T4MJ$UU8B,F?;\JQF.&W#K
MHB5?0W7W&V^O0NO4R(^_[<[7[@[MZC7I7;NUR[K>VYQ2.%8_*R7G2F.OYU[5
MKKPUUF(='W!W)T/M;86ZGU_<XMMLXY3:>-I_)I6-;7M^;2)G3CII$MHNE."6
M.8RN'D.V9,;+;ELT/M8M$[_TO"<[24E%DXXEN1?N-+_:@TM13,C2I#R?J>ZO
MIS]V3I'1K8^J]]7IO^HQI:-M77[-2?9DF=+9YB?"8KCYQ-<E>+4#O_[Q?5>K
M5R=,[+I?9;"=8G<6T^T7CVTB-:X8F/'6V3QBU)X-@C++,=EJ/':;888;0RPP
MRA+3+++220TTTT@DH;;;0DB2DB(B(NA#:K'CQX<=<6*L5Q5B(B(B(B(B-(B(
MCA$1'"(CA$-9\F2^6]LN6TVR6F9F9G69F>,S,SQF9GC,SS>09L
M
M
M
M
M
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MA6/R:5C2M*^RM(K7Z'+1WKI0
M
M
M
M
M
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M]2^Z^_,\SUG/->GQ;6FWQZUPT]GNZS-[1^7DFUN>DQ'!W4/1GX
M
M
M
M
M
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M!YEZ@^D?97J3MYCKNV\G5(KI3=8=*;BFG*)OI,9*1Q]S+6]8UF:Q6VEHFP\
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MWUW[J[N\^QZ7,],Z).L33%:?FY(_I,T16=)CG3'%*Z3-;>?A+,(>_O#0
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M]T
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MG]!&DP.VP
M                                    0[?;?[N>9?$GG5M3CQH.[UU7
MX+KFEUNTXUD6!0LCLEWV5:]QS.+)Q=G*?CJ4T3>3LH2VGN2CL,NO=W)396L3
M&LH:UO\ 61?9O_\ A3IW^U)4?_;QEY*A_K(OLW__  IT[_:DJ/\ [>'DJ-]?
MHB]E7,'V"["Y"1>05QA-EANJ<,PB16-XIA$/&'F\FS6\NVX:YDR*N0;[7Y5B
MLPDM&M'4^JNBNWJG"T1')*2@,
M
M    &K7GAZA>(G/.)8W^88K_  TW4]&6FOW?KB)"J\I>E)2CX_ZVJO&BEV'
M2;+;:RL6_P P;C)-J+-B]W<5&7;X\O&>%O:]A].?6_O?TXO3;;'-]KZ!$^]M
M,\S;'$>/RK?'@GC,QY)\DVXWQWY(3'/+U <N^!LFTR+*\7_B?I&-)44'>&N(
M<VRQF+#<>)N&>=TYH<NM=3W"=:0Y\]*JQ4IPF8TZ4KZGUV7;Y,7&>-?:^@'I
MQZX=D>H]*;799OL?<$QQVF>8KDF=./R;?!GCG,>2?F>6/-?'2&J\4/8@
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MD8Q']@
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M=V;M:S)Y4A$[8V=Y/FDEEY7D(UQW,CM+%4?HEY1$2.TDI49$1%]!EH.K
M 'FCR)$.0Q+B/O1945YJ1&DQW5L2(\AA:767V'FE)<9>9<22DJ29*2HB,CZ@
M-BF@O;;[$N-SD1K7O*;95I0Q/"VC$-F63>VL41":42CK8%3L9G)/T_#=Z'W?
ME:X+A=QFE:5&9B)K$B1/Q(^Z.Q2[D5.+\T]*KPM]];<:5MC21S[K&&5N.$@I
MEUK._FS,GJX$=O\ &^[7VMQ(6?\ 2H?]",)I[#5*#T?R#TCR5PB'L;0VT,.V
MIADSQH_.<1N(]C\"2XV3OY;>5W5NUQVY:;,C<A3V(TMK^C;28KTTYI=Q
M
M                    JYO;-FA9[[*.:EX3BG/@[]S?"^Y7=U(];S$Z[-O\
M4:(?:T>+=I?@,NA?1;A='%7U^&$->0D $VG[4W!_@:/Y;[)\/;^K-K:]P?S]
MO],_A[B-O?>'N_E\'\3N[I_)Y/\ ;%>0A*]%:0
M
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M@;89D3L3S2A-UV3C^1UR)"#6RLU-O-+0_'<>C.M/.53$QPE+(\0
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M*V:^_"EO$11I9.O-PD5VIIQCDE(\&
M                                                   *B7=6:%LC
M<FVMB$[YRSW9N>9H3W:A'F+*<IM;PG>QMB*VGR%.Z]$M-D77Z)27T*^.2'68
MD %A/]M7A'Z4]:<"^\7C_B9O7:V;]W^[? 1C6M_+_37/V?P^[/V-_P S^;_1
M*IO\26_\8@
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M91$:6M#5C!1,:<:>;-4>;$=:D,J4TXDQ3,:3HEEH(
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M1IW#9BS<04Z7C#-GEV>&EHUI0['C?J&A0V[V*+R>9"5$:'$BN\^!"7F*T@
M  #0'[Z_9G,X5Z+A:0U!>?E_(_D%36D:OM8$E+=IJ_5AF_49!GS"FG"EP,BO
M9?EJZ!XB1XY#4R6VZEZO0AS.D:SKX"O64I2U*6M1J6HS4I2C-2E*4?52E*/J
M9F9G]3%J'X _MMMQYQMIIM;KKJTMM--I4MQQQ:B2AMM"2-2UK49$1$74S 24
MN!'VW^^^0M%2;/Y495.XU:\MVHUC58*Q2,V^Z<BJGT$XAZ=66+[%1K1J4TX2
MVCL6Y]BDTFEZN:)25GA-XCD)&NI/0)ZO]51(Z9FBK/;%PPCQJR+;>?9=D,N2
MDT]JCD4%'98Q@IK4?U[D5"%)/^:9%]!A-[2EE"QZK_7#'998;X3<<%(8:;90
MI_5^-R7E(;02$F])DPW9$ATR3^);BE+6?U49F9F(UGVCGFOO7YP;U3DU=FFN
MN(_'C$<OII+$ZDR>HU+A;5]1SXKA.QK"CM7*AV;36##A$:7XJVG2Z?S@UD9?
MB   & GLIYTXIZ^N+.8;QMV(-UFDIUO#M189,>6TC+]DW466Y3Q99,J1(_(J
M2)$?L[-2%-J^%#<;;6EYUDCF(UG05AVSMF9WN7868[5V=DUEF.P,^O[#)LLR
M6W=)V;:V]D\;TAY26TMQXL9HC)J/'90W'BQT(990AI"$)OCAP0X*  -T'KK]
M(7*3GQ7UFR9CL31''N9(Z1]J9M4SIMIF$5IWPRW=8X0V[72\M88=(T'/DRZV
MI4M#B&I3KS+C)8S:(^L2H='?;E>MO55>Q^O<0S_D%D"6B-^XV9G]]35[<I22
M2ZNNQO64C!:Q$3^<3;4X[%2"5U-Q2R2LL)O*6<%;ZHO6W4Q2AQ>%/'MUI*UN
M$NRU]4W4KN6?51'.N$3IJD%T^B3<-*?Y"(8^:?:/O5?K']=U//C6<'A+QB*7
M$6;D<YFFL&LV$.&A2"<5"LJ:7"=6WW]R#6VHT+(EIZ*2DR:S[9&;D"!!JH,*
MKJX42MK*V)&@5U= C,PX,"##91'B0H42.AN/%B18[:4-MH2E"$))*2(B(A ]
ML              8[<HN5>C.'&I;S=&_LV@X;A]0DX\)@R*9D>6WKK:UP,5P
MR@:64[(LCLS;/QL-$3;+25R)#C$5IY]N8B9G2!7[>S/W.<A?8';6F$4[UCIO
MC*Q+[*C4-':K5.R]B+)0_#NMLW<0H_ZHL5OL-OM5J"345RTMDVV^^V<UVVM8
MCZT--8R    '*</P;-MAW3..8!AV4YSD,DC5'H</Q^VR:Z?21DDU,U=+$FSG
M2)2B+JEL_J8#8/KWTX>SO9K33V-\-=LUJ'NWL+83..ZD=+N;-TO*QM:^PM]C
MHE/0^]*>BOPGT49$,?-7VC)BD^W5]I5JI*9^I< QHE1$R#7=[EUT^E#QFT1P
M%%CEWD"SEI\AF9I(V/W:NCA_A[GGJ/1O_MX/:C3?+_+M)8=E?QO!X?R#=.J(
MWS_-X?)\3]4Y7C79\7RJ\GG\/7QJ[._JCN>>HPWVKZO/89I:/+F[ X?[RAUD
M!'EL+K&\,F[!H*]CL2X<B??Z]/*:6%&22R(W'7T-DL^PS[OH)\T3XC!%YEZ,
M\['D-.L2&'7&7V'FU-/,O-*-#K3K2R2MMUM:3)23(C(RZ&)'C     2V?2I[
MTK'$I^+\1^;N;.S\*EJ@8]IO?643$JEX2_T;AUF";0NY!D[-PZ0KM;KKR6M;
MU0X9,S'%5YH>KZ[5\8$TQ*DK2E:%)4A224E23)25)475*DJ+J1I,C^ABM+]
M
M                 '1O)[-2UMQJY#;%-[XQ8#HW;6:G(_!^X+%L!O[TWOWB
M5M_NB@=WXB,OI]2,A,<Q4EB]   +.CTOX6>!>KSAS1FV39SM:3LT[4]O0RV1
MFF4[$)S\,J675TLI[C_&1]3^J&SZMHHM\4I;/A
M
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MW_:/>W0N]-C]KZ1D_GJQ'S,5M(R8YG\JNLZQ/A:LS6?;K$Q&<(I?K@
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M+API;7R:[S'(2PA6D
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ME<0^U41@GZ[U\8$LL5I
M                                    &LWW)9L>O_6'S)O2>2P<_5"\
M)[U.);)1;+R7']<&SW*-)&J265^,D_M6:NTNIGT&5?B@5A8N0  "VHXH86>N
M.+7&O7BFO K M Z<PM3/<M7A/%]=XY1FUW./RG%>,X/3JIUPSZ?52C^IT3S2
M[^$
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MA5>3)3%7S7G2'=]![;ZWW-O(V'0]ODSY_'2-*TCVWO.E:1]-IC6>$:SP3*N
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MT2- KX$9B%!@PF&HL.%#BM(8C1(D9A#;$:-&8;2AMM"22A)$1$1$*DO9
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MNYQ^/*R:8^W#[UN*8KVH[!*-#211,ZSJEF&(                 !TKR)Y
MZPXM:8S[?.XK]O'< UY2N6UM*Z)<FSY+CC<.HQ^DB*6V=CD&1V\AB#!CD9&]
M*?0DS2GJHIB-9T%9=["N>^V?87O^WW%L5UVGQFN*50ZHUK&F*E4FML&^8Y)B
MU,=Q+,5NSR"Q4:7[:T6TAZ?*(B)+49F+&8NB-(T0P4$@ ^I24=UDUS58YC=1
M:9!D-]8PZ>CHJ2OEVUS<VUC(;B5]755<!F1-L;&?+=0TRPRA;KKBB2E)F9$
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MG6'>E%HTG1+8@(
M                              &@[[DG-SQ/UEY%0E()DMF[GU+A!MF\
MEHY90+"UV1\=*%/LG(-)Z^)WL)+ID31J[2))K1E3XA7E"Y  ["U)AB]C;6UE
MKUIM3SN=["PO#&V4FXE3J\HR2MI$-I-I2'24M4[H1I,E?7Z&1@+>-*4H2E"$
MI2A*22E*2)*4I271*4I+H1)(B^A#CI?H
M
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MN9C0:^#%:226VF6T-H270B(A ^N
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ME!%C>-8%B4*4@
M                            (J'W5V<*K^/O%/6I/FE&6;DS+.%1O(9)
M=5KW"6Z%+YL_+02SCELXTDKP.=GE,O(WW=KN=.:)0B!: #8!ZJ<)+8/L?X6X
M\IE4A$;D'K[+GF2;4ZEQC7MNWG\@G6TI5W1R8QE1N]Q=GC)7=^'J(MRD6DPH
M2
M
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M]R1-6VTN2;+5-IUGZ$MH Q
M                                      &K_P!T6;?H#U=\Q;WO\?S]
M:U^$]W;W]?XEYMBFN>SI\2;T\OZJ[>O87;UZ^1KIY495^*!6,BY   +;'B[A
M'\,^,W'76_B\/\/M%:CPCP_[E^E, Q^A\7]-?_I?P.G\]?[/YQ_M''GFEWJ
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MM=?O+D[#N<6@RZ^2EJSPK4[#3</8&6-N-+.57V5VU.12U;I);7WRI<F.ZEZ
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M&G7\4V)$9C]REQXC6:4DXXR5=#5%4VO]BB,Z)C2=$LQ!
M                                                           "
M$?\ =89S^8;YXFZT\_=^DM19WG/QO)U\/\0\R@T'G\7F5V?(_AAV]WC3W>+I
MW*[>B+,?BB44D6  W?\ V[V$%EWM*T[;KCJD,ZYPG<&;O)-E3S+1NZZO,(BR
M'R)AYMM+$_-&5-K6;9)?)LTJ[^U*L;_"+&<4I
M
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M#:7H\F-(94MI^.^TLE(6DS2I)D9&9&,1[       XIFV>8/K3&[#,MC9GBF
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MV_G+Z5-^-USQ;"NL%BONI-EI9^>OPAE3:C-?<R:#)7::4IIO\26\$8@
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M,&AQC%J6JQS'**L81%K:6AHX+%945-?%;(FXT&NKXK;+3:?HAM!$7T(4)?:
M                :,/N%.+C/(3U[9EG556E+SOC/;P]RT+[+*%358E%3^2;
M0K3D*_$S5MXA/7<R$E_3':-C_8&5)TD5U N0  ";G]K#OQW(M'<C.-UI--R1
MK'/\>V?BS$AWN<_3^S:J12WD*O;Z=40:>_P5$ETOV$_<=?VJ,5WYZD)68K2
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MM9R<&SR6MPR0;<+!\\AXUE-BIIQ1)6J-$>0E2D_BZ*29XS68YC.(0
M      #H+>/*CC=QIK&[7?N\=8ZECR&C>@QLVS"FIKBV0GO,RH\??E?GUZX1
M-*/LAQGU]$F?3Z&)B)GD-2.S/N0_6;@,J3%QS)=P[C.,?8;^L]5S(D5YPG#;
M<1&?VG;ZR2\3?3N\A?NEI^J%*ZD)\EAB;;_=4\9691(H>,.]K*%XB-4BWO-?
MTDHGO(Z1ME#AVV0-&T31(5W^<C[E*3V]$DI4^24:O7K_ +JOC>Y,91:\6]W0
MH"O)YY-?DV!V<QOHTLVO#!DRZEE_O>)*5=TAOM29J+N,B2;R2:LL]5_<C^M/
M84B/$RJ]W'I1U_L0I_9>L)%C7MOJ639(.7JFXV8M#*E'U)UUMI!(_$OL^I$F
MDI;@M(<F./?)2C<R+0>Y];[<JX[3#M@K!<MI[V?2_)Z^!G(:>)*5<8Y+<[3Z
M,3X\=[_S1CI,<QW@(       8V[IYB<6..5]58OOG?\ JK4.0WE05_34^P,P
MJ<9G6E*<V57?F4!FSD,*E1$SH3K1J1U)*T&1]/IUG29Y#IO_ #I?KC_QVN-?
M]M?%/^4 TGV2'^=+]<?^.UQK_MKXI_R@&D^R1W9ICEYQ9Y%65E2Z)Y#:<VW>
M4\;YUI0X%L+&<COH%?WMM_F4FDKK%ZU:K/*ZE'R39\'D/L[N[Z!I,<QD4(
M          &-^Y>8G%/CQ<0<>WGR+TSJC(K*,4Z#CV=;#QC'K^1 5]$ST4D^
MQ:M"@+471+YM$TI7T)1G]!.DSR'3/^=+]<?^.UQK_MKXI_R@&D^R0_SI?KC_
M ,=KC7_;7Q3_ )0#2?9(R4TMR$T?R-Q^TRS0^U,(VYC%+<+QZVR# ;^#DE/
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M_P!&9PU_[GJW^NUN/S^Z_M%_K?0'TQ_T#TK^ZQ^&S9(*'[L
M    8V\R_P#! Y6?Y-N\_P"YAE SQ?I:_P :/PNA[I_TQU+^X;C^JNJ?!^D?
M.$  $_[[9K_1SWG^4ELW_HKK<=+O_P!/_P L?OMS_0+_ $-?^_Y?Y&)(7'">
MV@           *U;WB<N7.6GL!VG)J+#Y>N='O+T3KM#2S5%>BX-8SVLPO6C
M(DLR?U!GTFS>9D)3^]KTQ4]RB;2H[JQI"&H(9  R6X=<:,KYA<FM.\<,.6N-
M9[.RZ+56%LELG4XYBE>Q(N\UREQI1DEY&-8C639WC,R-Y3!-E^)9")G2-1:L
MZTUUB&H==X/JO *AFAPC76*4.%XI3L?5%?08W61JFLCJ7T)3[R8D5)N.JZK=
M<-2U&:E&8H2YN                             PTY<>P'B9P?QX[KD/M
MV@Q:WDPUS*'7U8L\BV;E*"[T,G0X-4G(NG(;\A'B^?(1&K&'#(GY+1?43%9G
MD(FO+O[GKD#GS]KC7#W6]'HG%E+>8@[$SZ-5[!VK,8(UDQ81:"2U)UQB+SB%
MEY(CS&1]JD$I$KH9I*R*1XHU1V]U<D^0'(Z\/(]\;EV1MJU*0[)BN9UEUS?P
MZM;O=WMT53-EKJ:"(1+,DL0F([*$F9)01?09Z1'(=)        S7XT>Q;FKQ
M$EURM$\A=@XQC]<MOMP"UM3R_6C["5)\L9S7V6(N<4C_ "62-M3\:*Q+;0?5
MIYM1)443$3S%ACZHN6NU>;O"G7G(?<>.XCCN991>9O2N-X/%M:_'[:!AV3S\
M7:NV*ZXM+J7 DS9=6^E]HI3K7E;4IOL2HFT4VC2=$MCP@  !6L^^;-BS;VI\
MGW6)'GK\8DZTPF 7<A7QSQG4F#0[F/W-N.(_#DISCZ?0T]W11$HC(75^%#3^
M,ARS \[S+5^9XQL37F2V^'9QAEU R+%LHH9CD"WH[JL?1)A3X,IHR4AUEU!=
M2/JA:3-*B4DS(PMD.-FSIN[..F@MS641J!8[<TKJS9T^"RTMAF%-SW!:+*I4
M1IAQQYQEJ,_:J0E*EJ-))Z&9G]1QYYI=U ,?.3G*32'#[4M]NG?N;0<,PND(
MF(Y+(Y=[DUV\VZNOQ?$:-D_G9!D=H;2B:CLET0VE;SRVH[3KS<Q$SR$#[V&>
M^_E1R^L[S"=,6UYQIX^N+E08N-X?;N0]EYK5K)+'R=AY[6+9G1T3VDN&NHIW
M(M>AF0J/)78]B9"K(I$<^:&AY2E+4I:U&I:C-2E*,U*4I1]5*4H^IF9F?U,9
MC\  %L-PEU7_  0X>\8-2N1F8L[ =#ZMQZ[;CH[&G<EBX;4*RF;V]",EV&1.
M2I"_Y36X9BB>,I90"   'S;FZI\<J+3(,AMJVAH:2!+M;J[N9\6KJ*BKKV')
M4^RM+*<ZQ#@0(49I3CSSJT-MMI-2C(B,P$5WV&_<I8+K>;=ZKX(4E-M;+(3T
MFMM=[Y=&EKU?5/MI-A_^'^.LO0+//I+#ZE>.RDN0Z@ELI6RW9QG266<4]J$0
M[D-RJY%<K\O<SCD/M[--IWWFDO0$Y':K.BH$RS;.1%Q3%8*8>+XE7NFTGNCU
ML.*R9IZFDS^HLB(CD,?A(    RXXH\Z^57"C*"R7CKM[)<*CR)*)-[ACLC\[
MUSE?3Q(6638';_+QNRDKCM>)$WP(L8S:E?'D,J/N$3$3S$YKU<^\32O/1=7J
M39L*JTARA5&4;&'O6)_H39ZV",Y#^J[FTDJG*N4M)-]W'YJEV#3/5<9Z>VS(
M=9JM73ZDL"_NM,T.#IWB!KOR$193LO9^:&U^'N6>!8MC-&3A=8JU]&RV09'T
M>;+\9=4.?13<TYHE"A%H -B'J6PL\]]E7"RC)LG#@[ZPW-.U7;T(M;R'=B&Y
M^*5$+JT6+=Q?C,^I?1#A]&UXV^&1:+"E(  .';%RUC =?9UG<HD*C85AV3Y;
M(2YT\:F,<I)UPZ3G5U@NPVX9]?QH^G]$7[0%0C+E29TJ3-F/NR9<R0]*E27E
MFX](DR'%//ONN*,U+===6:E&?U,S'(0\   LH?0IA!81ZK>,J78YL6&6-[,S
M>Q-3*F3?/(ML9N[3R.UQAAU9+QEB"1+5WDLD]4*-LT"FWQ);A1B "%![YO9%
MS T%SSE:FX^<A<YU=AN*Z>UT=KC>)3ZIJ"[E%ZYD&1S+28TN#*D(L951;P6S
M\JB6;+31D78:3.RD1,<4-+W^>$]FW^.9N/\ ^)U7_) S\M?8'^>$]FW^.9N/
M_P")U7_) >6OL&NNYN+/(KBVR"[FO65S>64ZXM[&09*D3[.SE.S9\U\TDE)O
M2I3ZUJ,B(NY1B1\T  9TZO\ 9GSTTK@6-:NU3R?V5@FOL/ANU^,XGC\JJBU%
M-$?F2;&0U$9.K<47R)\QUYQ2E*4MUQ2E&9F9B/+ Y[_GA/9M_CF;C_\ B=5_
MR0'EK[ _SPGLV_QS-Q__ !.J_P"2 \M?8'^>$]FW^.9N/_XG5?\ ) >6OL&;
MWK9]C_L6Y \\N*FH\MY8[:R7$,KW'BSF88[-LZTX-]B../N95E%//2W4>1<"
MRH:.0R^E)I-32U$2D]>XL;1$0-X7W'7-/D)Q,Q7B?4\>-LY/J>^V1D&W['(K
M'%'&6)UI48/7:\C1(4IZ0U)91$1,S0UDDV^Y:TD:5$2%$K&D1/-**_\ YX3V
M;?XYFX__ (G5?\D"SRU]B#_/">S;_',W'_\ $ZK_ )(#RU]@PFW#N7:/(#85
M[M?<V;WFQ-BY,BJ;O<MR)]N1:V3='3P,?J6WULM,,DB#35<=A!)0DNQLNO4S
M,SGER'60  ROT#SFY<<6<;N<0X][YSO5&,Y#>'DEU38K+A1X=C>G AU9V<A,
MF%*6J2=? 9:ZD9%V-E]!$Q$\QWO_ )X3V;?XYFX__B=5_P D!Y:^P/\ /">S
M;_',W'_\3JO^2 \M?8'^>$]FW^.9N/\ ^)U7_) >6OL'E9]OWL\DO-1X_,?<
M[\A]UMEAAF?6.O//.J)#3332*=2W'7%J(DI(C,S/H0>6OL%FQAU=<5&(XK4Y
M%9NW>05>.4==>W+RDK>M[B%618UG9NJ2VTE3L^:TMU1DE)&:_P!A?L%"7(P
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M_OMFO]'/>?Y26S?^BNMQTN__ $__ "Q^^W/] O\ 0U_[_E_D8DA<<)[:
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M(U)C.*4=3C6.TT)*DPZBBHH$>KJ*R(E:EK3&@5\5MILC,S)""ZF8H2^X
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MKO*<FG*F3Y'87;'B1FTI;AU=3 9Z-1845IB'$92EIEIMM*4E;$:<D.L@
M     !MS]4OM<VGZ[-H0*JSG7.9<7\QO&E[4U6EPI2ZPYOQ(DK8>O694AABL
MSBJBQFS<9\C46XC-?&DFE91I47&U?-]8L>=8[,P3<VO<.VKK#)JW,=?Y]05^
M38GDM0Z;L&UJ+)DGF'4I6EN1%DLF9M2([R&Y$60A;+R$.H6A-*7.@   >M-F
MPZV'+L;&7&@5\",_-G3IK[46'"AQ6EOR9<N2^MMB-&C,-J6XXM1)0DC,S(B
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MAUGH_L;D=L+(&9"D]%.5=+BNO\,C,)/Z$IEBRQR:HOY>]U?U_8157YIA(J&
M     -3/M#]M&E_7#A2*N0W$V/R+RVH>FZ[T[#G&QX8BW'(C.:;"L(R'G<;P
MR/+;632.A3;=YE;$1))1)E1<JU\PKVN5W,'D%S5VA/VSR$SZQS&_=5(8H:=*
MG(6'X-3/NI<1CF"XRAYR!CE*UXT=R6R5(E.)\\IU^0IQY=L1$<D,9!(
M    .R-1;>V7H;8N*[9U!F5U@6PL+M(]OCN34,GX\R))861K8D-+2Y$LJN<U
MU9EPI+;T29'6ME]MQI:D&F-8TD6,OJ4]JV"^Q_5DF!<L5>%<E=;U<%6UM=QI
M!(@V\):VH+>R<!9DONSI6&6DYQ#<EA9N/TLYY$9];B'8<F73:LQ]26WD8@
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M.Z-3FA.T]0[0UHIQ9MMIV!@&5X::W"6;9MH+(JFM-2R<2:>A?7J703J.KP
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M9:ZVT\$) OVU7^C3@_\ ?MM;_P!#&1C?XDM_XP
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MN@QI\27G^VJ_T:<'_OVVM_Z&,A?XAO\ Q@
M      -57NZ_T67+S^P_#?[JV!#D;3^T5^O]YYUZM?[=]3_54_KL:L_'?M"
M  6>/I__ -&9PU_[GJW^NUN/S^Z_M%_K?0'TQ_T#TK^ZQ^&S9(*'[L
M           8V\R_\$#E9_DV[S_N890,\7Z6O\:/PNA[I_TQU+^X;C^JNJ?!
M^D?.$  $_P"^V:_T<]Y_E);-_P"BNMQTN_\ T_\ RQ^^W/\ 0+_0U_[_ )?Y
M&)(7'">V@          KXON5=MNY_P"QR3@#;RO@Z+TWKC"%1"5U;1<93%G;
M6G333VD:9$JKSVO:5]3(T1D?[8MI\*)1]AF #*3A#IQKD%S!XS:8EQU2:G8>
M[==8_DC:4>12<1=R:OD9@^EOZ$X<7%H\QTDF:25V=#,B^I1/(6P0H2
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MB+NXC[T=;$R!KJE<7.AZZHG$/.H,HKCME*:<-$N9(03:&ZIM,_4EM@&(
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M=2W^/VEA27E-9QG85E4W%5+=@6=980WTH?B3H$UA;3K2R);;B#29$9"Y#Y8
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M%MC6B67&VY4%V9$63E=>;5:4HEOR5$]%IG4DW#-3[:I:ZK6UX1R$ET8)
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M<E7NB\B1W$CYR-CUJXN(PNY7T_'LN!1.=/VJ\?:7U,C&-_A%E,*4@
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M)A-/B#[:K_1IP?\ OVVM_P"AC(7^(;_Q@
M     -57NZ_T67+S^P_#?[JV!#D;3^T5^O\ >>=>K7^W?4_U5/Z[&K/QW[0@
M  %GCZ?_ /1F<-?^YZM_KM;C\_NO[1?ZWT!],?\ 0/2O[K'X;-D@H?NP
M            !C;S+_P0.5G^3;O/^YAE SQ?I:_QH_"Z'NG_ $QU+^X;C^JN
MJ?!^D?.$  $_[[9K_1SWG^4ELW_HKK<=+O\ ]/\ \L?OMS_0+_0U_P"_Y?Y&
M)(7'">V@          JS_:3L!>S?8MS/RI3R)+2.0FQL4@R&C)34BJU[>2-?
M4\AE:7GTN,O5>,,J0HE=%),C[4]>TKZ\H0P)$@ WB_;MZ\;SGVAZIN7VDO,:
MMP/;.PW&E^ VS<5A<_ H+JT/+2I:HMEG;+S?C)2TNMI5T)*5*+&_PBQA%*0
M                       !!'^X0]I4G?\ LBTX4:2R!TM(:CR/Q;;O:J4:
M(NU=K4,CM<HC=87UGX3K.S:4TVVKHQ-OFG)/8XB'7R!;2NG&>:$9$9@ S:X"
M\$]N^P3?M)I35[/Y55M(3=[)V-/@R)>.:TPIATD3+ZU2RIDYME,<_J:KKTN-
MN6$YQ"#6RPE^0Q$SI&HLJN('$#2?"'2>.Z-T;CI5./U)%.OKZ<3#^59[E3[#
M+5KF696K3+!V=[9FPDOHE$>)'0W&C-LQF6FD4S.O&4LHA      (L_W4^;?
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M)S_*-083'6E2T.K)6SL9RR=':4AQ'_UFIQ20VX1DHE,J673Z]2RI\0KBQ<@
M<QUWB3^?; P7!8IK3)S3,<9Q*.IOKY$OY'=0J=DV^C3Y]Y.3"Z?@7]?Z$_V
M+>V)%C08L:%#8:C0X<=F+%C,H)MF/&CMI988:;21)0TTT@DI(OH1$..E[
M             (V_W06P/TYP.UM@T9Y")FQ^1V)LRF%&P:GL>Q/"L]OIRVT*
M>3)[V;[\J_$AM2"2HR6I)J02\Z<R4"$6H  !9[^G+7J=9>L;AOCJ8ZHYVNI(
MNPEI4EY*G%;8O+K:/R#^0RPXI,A.8$M)]#1V&78I:.U1T6^*4MEX@
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M7:.PTQV4I(U+==2E)&9D0F.,Z"I=SG-,CV1FV8[$S&Q=N,NSW*<@S3*;9_\
MIUID>4VTN\O+%[J9GY9MG.==5]3^JA>AQ8!]*FI[3(KBJQ^C@2;6[O;*#3T]
M9":4],LK2SE-0J^!$93^)V3,EOH;;27U4I1$ M8^#?%W'.&O%/2_'?'F(A/8
M'A\%.7640^].1;#N>ZZS_(U2%-,OR&K;+)\I<8G"-3$/PL%^!I!%1,ZSJEEB
M(     !J5]YN"P\^]6G*N'(;:.3C>/X9G59(<5VJAS,,V3A][(<95V.%Y951
M%E13(R_$B0HB-)F2DY5^(5H8N0 ,^?5CDSF)>QWA-:M2EPU2^2.K,9-YMM3J
MEMYKD\+#7HII2E1DB<U?*84K]B$N&HS(BZB+<I%I:*$@   (]WW*6A%[3]?2
M-I5L%<F[XZ[0Q3-GWV$$[)1AN8.KUUDL9#9$IU48K7(ZF:^:"_=M0#<7T;0M
M19TGCH*^H6H '*\$S*[USG&&["QF1\3),$RO'<RQ^5^(OC7>,6\.[J9'5"DK
M+PSX+:OH9']/H8"W U=L*AVWK+76UL5=\^,;-P3$=A8V_P!Q+\U#FF/U^24[
MO>1))7DK[)L^O0NO4<=+G8      UI>VGFQ'X*<+-D[2JK!F+M+*V?X9:5C*
M4@Y"]C9;#FM1;UIE?<3K.$4T:9=.$I/C<5 0PHR-Y/6:QK.@K#)$B1,D/RY;
M[TJ5*>=D29,AU;\B1(?6IUY]]YU2G'GGG%&I2E&:E*,S,^HO0\(#M;1FFLWY
M#[BUKH[6]?\ F6;[2S&CPS'F%DY\9B9<S6XSEG9.M(<5%IJ:*;DR:^9&F/$8
M<=5T2@S">'$6K7&/CW@?%/0>K>/6M8ZF<0U=BL/'H4EUIMJ9=6!K=GY!D]FA
MHU-_F^4Y#,E6,OM/L^1*7V]$]"*B9UG5+O80    .G=_:!U)RBU)EFB]Z8G^
MN=5YS^0_JG%OS[)L9_-/TSDU-F%)_P -X?<X_D<+X61X_#D?U/,9\GA\;G>T
MM:%3$Z<8'4?$[@7Q/X.Q\YB<7-4_PPC[*?QV1FK?ZYV3FOYT]B;=VUCZ^_8F
M8Y:NN^ C(IA=(AL$[YOWA+[$=J9F>8R^$#$?E?P4XJ\X*["ZGE#JS^)]?KR;
M=6.'Q_UOL;"ORB9D3%=&N'O+KS+\2?L/F,5,=/;*4^AOQ]4$DU*,YB9CD.\]
M2:GU_HK6F%Z?U70?I;76O**)C.'X[^:W5W^3TD$E%%A?F^1V5O>V'B)1_O)4
MI]Y7\JS$<^([%  &/_)7BWHGE_K1>G^16"_Q#UTY>U63+QW]39CB7==TA2BJ
MYOYO@V0XS>E\4ICG[LI7A7W?C0KH728F8XP'&KBWHGB!K1&G^.N"_P /-=-W
MMKDR,=_4V8Y;VW=V44K2;^;YSD.37I_**&W^[.5X4=OX$)ZGU3,SQD9 "
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M^^)K_C7B#,F/Y.[P7V3YWL6[FJ[$O+0WYJ,ZP^AH0X?;U/N3V=+:<D2C;C,
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M.85T-$BNP_+*[,+*,X1_M;D0*)Q"NG0^U1]/J(MRD6GPH2
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MXIB5'58UC-!5,)BUE)0T<%BMJ*JOC(_ Q#KX$9MIM!?S4((A0E]\
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MQ_781#(E))1Q]HY]5*>1^(NY*<=BRF3_ &E;QU?RD*[SX$)B0K2
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M_P ?S]:U^$]W;W]?XEYMBFN>SI\2;T\OZJ[>O87;UZ^1KIY495^*!6,BY
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M]"6IU7CE'73&TK0ZEN7"K(L:0A+C9J;<2AYHR)23,C_:0XZ7(P
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M*8Y",TKDN1H#7]4V=E(0AOYMU=SW'ILZ29$N3,D.NJ_$LQ1/'BEVP
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MEDY,FOF1*D2WW'5?B69BF9UG5+M80
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M88@YG#.<;!C/M>6%)P/6\61G&1U4\NI=D;)HM&522OVD[/0(M.D:BT>%"0
M      !'Z^Y9S;]*^M9ZB[^S^)>^]5X3V]O=Y?@1<LV-V=?B2.SI^@.[KWL?
MS>GD/KXG,Z?$*]X6H '8&IL+<V1M36>NV4K6]GNP,,PMI#9J)Q;F4Y'6T:$M
MFG\1+4J<1%T^O4!;QMMMLMMLLMH:::0EMIIM*4-MMH224-MH21)0A"2(B(B(
MB(AQTO[   !53^QC-CV)SXYE9<F1\J+9<E]S1JN1W+5Y:*ESV\HJ!75;CIE_
MP)6Q_H2NU/[$]$D1%?7DAAB) !.I^UBP@ZOA_P @=A.1O"[F'(IS&67EMK;=
MEP,&USADYEYM2HR">AMSLWE-H6EYQ/F0ZGM0I*C75?F0D^C!(     JV/:KF
MQ[ ]CW-/(#D?*3&Y";#Q)E\E+6E<;7UR[@,3Q+6X[WLHC8RA*#2?8:"(T$2>
MA%?7DA@ ) !.?^U>PA-=Q+Y%[%-I*'LNY#,X@3AH)+CT7 M<XG;,J)1LI4N.
MB1L)Y*3[U)[R61$DR5W57YD)0XP2        @'?<\YM^HO8+A.+,K_J;7W&O
M ZA]GM_9;WN:;&RF5(\BHC#A^:JMX".PG'VD^+J1I6IQ";:<D2CE#, $F?[6
MS"?S?FQNS.GD>2-A?&NXJ6/Q=OAM\QV/KWXLC\,MIQSI58[/;[#9=:_>]QFA
M:6^["_(A._%20               $)+[K"'*1O7B78+96F%*U+GT./(,B\;L
MJ#F%:_,92?7KWQVK%A2O]IPA9CY(E%&%@  "X/Q^V3?4-)>(85&1=5%;;)C*
M63JHZ;&&S,2PITDH)Q31/=IJ[2Z].O0AQTOK@                   Z;Y$
M[8K]$:"W7NJT=CM0M4:JS[83GR5I0V^[B6+V=Y%A))1*-Z182H2&&FDDI;SK
MB4(2I2B(YCC(J1Y\Z9:3IEE82'9<^QER)TZ6\KO>E3);RY$F0ZK^B=>><4I1
M_P IF+T/5  $O+[4_392,KY9\@YL123J,>P+3>-SNU7:\6165AFV;1"6:222
MHQXMCZS(E&?[XNI%].M>3P(3-!6D :?O?/FQX3ZK.3[K$CP3\HC:TPF 7<M'
MG+)=MX-$N(_<VXVO\6-)G'T^I*[>BB-)F,J_$*UH7(  !-0^V!X6QZ' ]E<Y
M<QJNMWG<FQU%IIR4RA11,+H9\=[8N40%*-Q*EY#EL%FH;=(FWF"I9C?53<E1
M"N\^!"6L*T@       *_;[FK-OU/[&*;'4.]6]<<==:XJXPE?5")EKD6>YVZ
M\MLI<A*9+T3,(Z5*-#"E-MMD:#2E+B[:<D2CQ#, $@'[:G"SRGV5Q+PFO(6M
M]#[5S12^Y9> ISV+Z[\O1+[*5]59Z2.BDNE^/KVD9$M&%^1"PE%20!C+S/WJ
MWQFXG\AM]>1E$[6&ILSR7'D2.TF)>7M5$B)A=<Z:B,B1:9;*A1C/H?3R_L/]
MAS$:SH*GJ7+E3Y4F=.DR)DV9(>ES)DMYR1*ERI#BGI$F3(>4MU^0^ZLU+6HS
M4I1F9F9F+T/   +&;[?'CDUH?UQ:ZRBPJR@9?R&O;_==^ZZWUENTUL^WCVOF
MO.I).'7/8+CT*P8:(_&A=DZI)=SBS53>=92W@#$             &E7[@/>S
MNDO6=MROKIZJ_(-X7V(:-I7D.=KCD;*9[U_F<3L_G.M6.NL3N(JR^A$E_J?7
M]AY4C6PK@Q<@ >1EEZ2\U'CM.OR'W6V6&&6U.O//.J)#3332"4MQUQ:B)*2(
MS,SZ$ MAN%^AXO&'B?Q\T''C1XTK66JL2Q^_^*39,2\Q56-6.<VB/$E"%'<9
MC.G2U'TZJ4\9F9F9F=$SK.J63@@         $1+[K^=%;PWA'6K>),Z7DV^I
MT>/VK[G8M?5:FCS'B423;(F'K-A)D9D9^0NA'T/I9CYHE#&%@ ,S/7+%DS/8
M+P:9BL.R'4<O>-\I3;2#6M,:#N'#YLQ\R21F34:)'6XL_P!B4(,S^A"+<I%J
MT*$@  K_ '[F[-U9-[$L>QE#JCCZYXYZZQQ<<EF;:+"XR;/LUD2#1YG"3(D0
M<GBH4?:V:D,H+M,B)2K:<D2CMC, $E+[7;""O.=>ULTD1S=BX)QJR=$5_P *
ME)C7N5; UU6PU&^;#C32G:2+9I)/>VZOJ?;W(2X0POR(3U!4D  %4U[ =]+Y
M.<U>3&\4R_G5F<;9R=6+2?(3O=@N.R$XEK]OR)(DK\&$4->WU(NA]OT^@OCA
M"&'PD $R'[530;2*WE+RBL81*>D3L8T'B%CXNBF&H;$;8>QH1/&9]Y2USL5<
M-)=.WPD9]>Y/2N\^!"8**T@        #&OF;_@?<KO\ )KWI_<ORD3',5-HO
M0  "R<] _P#HD^)W_P"7;_\ 27W(*;_$EN*&(CR_<U8F_D7KBI[AIEYUO N2
M.L<LE+:5T1'8F8QL;!DO22\:^YE4G,VVR+JC]XM)]?IVJSIS)5^8M0 -UGV^
M.=P,)]I6CH=BXTQ'S['-K8(W(=0:DLSYVNL@OJMLED^T;3L^SQUF*A7:Z1K?
M)/:7=Y$8W^$6/0I2      "O8^XLYA1.1O-O^#^)VJ;'7O%.HL-<MKCR%O09
MFT[F7&L-K3HZ>\FVW:R77U]"^GL)12:-T^Y2%)Z6TC2-4-  S !/A^VBXF/Z
M<X@Y5R-R>K^'EW*#*&I= J0T:9C&IM=/6M#C"O&\DGX7Y_E,RZF_A[43()P7
MOQI\9E5>=9T2DBC      $-O[JK026;7BWRBK8*NLZ#E&ALRL>A$A"JU]W8&
MMXOT_G.OHLLI4HS_ &)921=?Y+*3X(E#]%@ -KWI'WM_ /V7\:KB7*^/0;&R
M67I+(D&[X6Y,?;%>_BN.I>=/JE#,/.Y51+5W%VF4;H9IZ]Q8VC6!9D"E(
M"O%^X/YP?WTO,N;J+#[?YNHN+'YOKJH^*_Y*^\V=(DQ_XJ9(GL/L=^':US%&
MRK\2.RH4\T?;)5UMI&D:H:$QF ":G]LAP5;QK!\SYY9[4K3>Y]^;ZPT8W,93
MVQ,'JK%IG8&;1"<;7U>R/**TJ:*\@VW66:J<G\34LC%=Y\"$M,5I
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M+"4PRXIY)FZ<?+G'#;2A9J0VI75)-GW87Y$)U@J2
M  ""#]T!R%5GO+S5W'NMF*=I>/\ K!%Q=1DNF26,_P!NOQ+VP9>82DDJ-G!J
M3'W6UJ4HR^4X1$DNIKMI'#5$HRXS !(;^VKXZ-;;YZS]O7%<J5CG&K6]WE\2
M0MORPT;!S?NP3$(DE!F3?E_(K*]GQU*)1MR*U"TEW))2<+SP%@6*D@
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M9-KV3G^XLV=Z="4XJ)L"WU\VXX7[2-4?!$=.O[4$DR^AD*;_ !);R1B
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M'L-C2DM>%=O-JX+:;K(93?51)GY+=KDV$GI]#D25F70OH*)G6=4N[Q
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MM,$MYY75Q]Y2G%F:U*,Z$N=
M                 "$S]REZ_P"PPK9=3SQUO1K<P?9GY/A^]&:Z+U:QG9%?
M$;J\5S2:A@^V-59W10V8#[OC0TW;0$J==4_9MI/MMAFUK\FW..7U?\/_ )R:
MG>O/9=]IOZ]X["G_ &FX\M-QI'P98C2F2?9&2L169TTB]>,^;)"*@.Q:Z
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M;T=A]BXVVEYB!C->SG&>M1UJ3YU1+.;D= 2C(R;-V!T_$I!]M=Y\"$N<5I
M    !^*4E"5+6I*4)2:E*49)2E*2ZJ4I1]"))$7U,!4=<A=F/[IWYNW<$EXY
M#^T]M[%V(MXT.M$O]9Y?;Y"@D,O]'F&D(L22AM1$;:2)/0NG0<B.$:(=/@ "
MPC^VKUBC!_6W"S)4<T2=S;JV=G127&5H6_!H'JC5D9EIU:$D]$CS->R33V&I
M"77'2Z]W<157^)*0&,          5R7O_P"52>2?L)SS&:*S3/P'CA71]'8W
M\=XEPW\CHI,BQV;9>)"EM)G)SRPEU:W$J/RQZB.9].G:5U(TA#2,,@ ;P/MW
M<&_5_M)T_<*8^0QK?"-OYR^E3?D:;\NO+O!8K[J39=07@L,V94VHS;[7B09*
M[B2E6-_A%C,*4@  Q1YWYH6NN$O+O."<4W(QGC5NZT@&GN)3ELQKC(RIV$K3
M&F$TJ3:*9;)Q32VV^[N6781B8YBJ'%Z   6DOJHPD]?>N#A;CRF4QUR>/FOL
MN=9)M+1H?V%4MY_()UM*4]L@WLF4;G4N_P AGW?BZBBW.4M@(@    8_\L<U
M5K;BQR6V*A:FUX#Q_P!R9JAQ)&I2%8MKK([U*TI)J0:E).!U(O&OK_Y)_L.8
MYBI9%Z   6CGJ<PI. ^MCA71)0E!3] 8+FIDDR41JV57_P 15KZD\_\ B<7E
M1J,NXNAGT[4?S4T6YREL*$        "J1Y^9Q_$GG'R^SA#WGB9#R4W3+JW.
M[O\ ^!&]A7\2A;[_ -B_#31V$=2Z$?;U(B+Z"^.2&(XD $^7[7_"58_P$V'E
MLAM29&?<E<TFQ7>ADERFQ[!=<8]%21'_ #E-W$2PZJ+Z'W$73JDS.J_-,)((
MP                $8?[IC7JKKA]H;93$<GG\"Y!MX[)<)+/DB5.P,"RI^1
M(-:V3>3'5;89!:42'4D:W4&I"^A*;SIS1*"B+0  %FKZ3]I,[9]8/$ZY)]3L
MW%,&L=6V3#AH-Z$]JS*+W!*]AWQ_@)+U#10Y#1=3/P/H[NBNI%3;XDMJ(Q
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M:[SX"4B*T@
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MC6M:QY:QI#7#>[[>]2W5][U#+DS[O).MKWM-K3/TS,S/#E'LCA'!PL9.*
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MF*$N3
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M;$B#D^@\OL?%T2P["D2=AZYA&^1F:U2T3\J<))].WPF9=>Y72RD^")0^A8
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M8AN*:+ M!;BS0W4]W<V6+:[R*\-Q/9&FK[D?!ZET9>/Z?1"OYIS',5*PO0
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MI*HP
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M..=:5B)7]8[X[MZ_AG;]6ZAN<VVGG3S>6D_QJ4BM9_9B6%XN?E0    !NNX
M>C+EIS6*BSO**YSCYH.R5'F%L;/:F261Y34N*)1OZZP%QR!:WS4EDR4Q/F.5
M]4ZA7>U(?-)MGQ,V\Q8N$>]?V1^_+U?LOTA[E[L\F\W%?L71K:3\W)$^:\?T
M6/A-M?"UIK2><6GDFT\(_6=Q+X#4"(VDL :E9[,KDU^2[DS4XV0[1R1M1]TE
MA=\J)&C8Y42EI1WUU/'KX#IM-K=:<=1Y3ZG+N,N:??GW?9X-L>TNP>VNS,/E
MZ3AUWDUTMGR:6S6]OO:1%:S^32*UG2)F)F-6?PI?M                &M[
MVV<6W^7G 3?VJZ:O799U4XT6S=:1X[)OSY&=ZU<_5-;3U;?:HCL,OKH4NC09
MET(K-7U3_.*:SI(J^A>@  &QKU7\Y+#@%R_P7<4M<R1K.\0YK[=--$)]YRPU
MKD<N$JQLXT-A+BY=MB%E#BW$1M*?(^Y!..2DI?68BT:P+//'<AHLNQ^BRS%[
M:!?XSD]-69#CM[526IM7=45U"8LJBVK9C"ELRX%E7R6WF74&:7&UDHCZ&*$O
ML@                   P)]I?\ HX^;7^37M?\ Z*6 F.<?6*L\7H  !9Z>
MFW($Y-ZP^&UBF1(DE&U0C'S<DJ)3B58GDN08JN.DR6Y_4\1=,;31=?HTA)=$
M_L*FWQ2ELR&(      ""]]R;[ F]P;BI>$VM;KY&OM"VIWVW)4%]*HF1[ID0
M7(D3'G%H2HGHVKZ*<\PYV.$D[:RELO-^2"THK:1XHE%Z&8  #/SU78-_$3V-
M\+L;-CY33/(37>628YM^5#T/7UTSG\UM]KPOI<C*B8RORI4GL-ON)1I3U446
M^&1:5"A(  -8GN<S5. ^K[F/>J62"GZQBX5W*22B-6R<PQC724=#9?\ JXK*
MB21]I=#/KW(_G%-?B@5B@O0  "W9TIA9ZWTUJ37:FO K M98%A:F>Y:_">+8
MK549M=SC\IQ7C.#TZJ=<,^GU4H_J?'2[-       !@E[0(<J=ZZ.;C$1E;[J
M.,6XYBT-D1J3%KL)M[":\?4R_!&A1G'%?^:@Q,<X%6,+T   M(?5%DS66>MO
MA3:,R7I:(O'O7V,FZ^XTZM#N%U*,.?C)4T\^DF83]"IEM)J)2&VTI4E"B-":
M+<Y2V"B       &N3VE<\<>]?G%#,=LF_ E;2R-$C!]'XQ+-E]5UL>V@R3@V
MLNN6XAR5C6&1T+M+,_PH6TPB-WI>E,]TUC616&9%D-WEV07N5Y-:3+S),GN;
M/(<@NK%Y4BPN+NZFOV5M:3Y"_P ;\RPGR7'75G]5+69G^T7H?'   !8$_;+8
M+^EO71<9,Y&['ME\A]D92U*6SVNR*^GH,%P-AEM]4..MV'&GXA*-"2<?0AYQ
MWHM*E+;15?XDPD.C   !$8^ZZS<XF"\,=;M/I45]EFY<WFQ4/)-31XE3Z_H:
MM^1')\E(3(+-9B65J:,E>)TDJ+M42K,?BB4, 6  V<>F?"BS_P!G_#>B-HWO
M@;2=S7L2E2C(]:XGDFQB=Z)<:,B8/%>\SZF1$GJ9*(C2>-OAD6=PI2     (
MH'W66;)@:1XCZX-Q)*RK:FQ,V)KZ=RTZ_P 1IJ)3A%^WM:/99$?_ .^0LQ\T
M2A,"P &S/TV8/_$+V>\-J'P^?\OVLG..SM[NW^&.,Y#LGS=.A]/C_I/R=?Y.
MWJ(M\,BSS%"0       &GKWUYN6$>JWDTIJ0;%AEC>L\(KB2\IDWSR+;&$-7
M$?N;?8=62\98G&:$]Y+)/1:3;-8RK\0K7A<@ ?5H:6?DEY38]5->>SOK6NI:
MUGHXKS3[28S!AM=K2'73\DA])=$I4KZ_0C/Z +??&Z&#BV.T&,5:$MUF.4M5
M0US:6F64MP:B"Q7Q$)9CMM1VDICQTD24)2A/[$D1="''2^T
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M/J;0Q'9V.Z]KMQ^0Z\AQIB.TG*NYQQ7:3:"-7<CIW%%OAD6C@H2
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M6JD>.KQJCJ:"M;[6T=D"F@1ZZ&CL:2AI';'C)+HE))+^0B(<=+[@
M  PG]CN@O[Y[@SR>THQ#_,+G*M4W]CB,,D=ZI&>X43.=8 RG\231YLSQJ"@U
M%U,DJ/Z*_FG,3I(JL1>@ >_56EA1VE;=5$MZOMJ>?#M*R?&5V2(5A7R&Y<*6
MPOH?8]&DLI6D_P"122 63'//V/0N/OJYI^7../M5^P>0&I]<L:.AD:'%,[!W
M9@;.35-HV7XVG&L(Q]Z;=&2NK;WY:EDSZNIZTQ76=$JUZ1(D3)#\N6^]*E2G
MG9$F3(=6_(D2'UJ=>??>=4IQYYYQ1J4I1FI2C,S/J+D/" ST]:?#*[YW<O\
M5NBHT:=^BEV*<QW!=0C<;/'M38O)B2<LD_+;_%!G7A/,4U>[T42+.SC&HNSN
M,HF=(U%H]1TE/C-+3XWCU9!I*#'ZNOI*.FK(S4*MJ:>JB,P*RLKX;"4,1(,"
M%'0TTT@B0VV@DD1$0H2^H
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MR^27'O7"&U/+V!O#4^$I:21FIU65Y[0426TD7U-2SG]"_P#I">0MMAQT@
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M%Y'2V5SB&6UL>1*_)LHH)+GCDQS6M!D:'F5NQW67G*9B8G24L@1
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M#EUTR77SXST.=!DOPYL20VIJ1%EQ75L2(S[2R);3S#R#2I)D1I41D8O0]8
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M.O32_P#)5"S.MKVZ/.Z=]_\ G.R:3,ZN?$<4?0U+9,^A=11,:3HEE2(
M      56/L>T&?&/G1R?TLS"374^+[8R&RQ*$AI++<? \V4SG> LH0@_'T9P
MW)8*#-/1)J2?1*?YI7UG6-4,)Q( -B_,3FU/Y#<<.!7'BNES/TSQ;T=-H,@C
MNH<CM3=DVN46M6MTDF2?GPZ;7.-T+,5Q?])>DS$MD2%FIR(C29D:Z!( +!+[
M=K@JYQHXF.<@<YJ41=L<JF:;+8B)+)E/QS3,)EU[752?E;[HSV5E.?OWS:5V
MOQ9L!#I$[&Z)JO.LZ)2%!@
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MK-5^ _CGBVI<ZLZA[M6I)J_^\3<)'TZFGO[NGT,8V^$65@I2
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MQ3,<UDNDTAMV4>=[/S?+X;TA:6&%/K;J[EAE"E$HR9:0DE*2DC.FWQ);7QB
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MTAB-$B1F$-L1HT9AM*&VT))*$D1$1$0I2]D
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MAR;U]CT-3DF0W$9[E;MHJJ*R:WG&HS?;E*&OQ&A"+,VS/\RD"REO"4(;@L
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M1C'&C1]3/+M[#<M8VML;*WD*;*1+2TN59F\XI"75H0:S))FDB%$\TLK!
M     @I?=.9J5GS$T#@#;R'6L0XXQ\D>2VZAPHT_-]D9Q">C/(2^LV)/P<+B
MNFE3:%&TZVKJI*D]MM.2)1AAF #=+]OKAA9=[4= 376O-$P>DV[F<ILU(2GK
M&U1E]!7.J,WV'#^-=9#%=(D$X9J01*3X^]2<;_"+($4I    5XOW!_"&9Q@Y
MH7&Y<9J_!J+E7)MMCTST5AU,2DV:ER*O:V.27C-392;&^GIOV?Z6@V;<V6TF
M459BVDZQIXH:$QF #WZJUM*&TK;RCLI]-=4T^':T]Q53)%=:55I72&YE?95M
MA#<9EP9\&6RAUEYI:7&G$DI)DHB,!-3]77W%.$9A38YH[G[<1L(SN S!I<=Y
M&''6C"\T::9;B1_XJ1XC;AX9E#CB$F]<-(_)91N*<D)KB;-;]=J>,"51C638
MWF=%691A^0T>5XS=QDS:;(L:MH%[16\-2E(3+K+>KD2J^?&4M!D3C3BT&9&7
M7Z"M+[@  ZXVAN'4^DL9?S/<6RL$U;B<;O)S(<_RJDQ*I4ZVV;IQF)MY-A,R
MIBT)_ PT:WG#Z$E)F9$',1F^>?W,&IL%@7>O^"V/+VUFZT/P/XT9M46-+J_'
MW%MN,KG8MC$_\MRK.;*&Z1^-4QFLK"<)#J53V3-M5D4]J-4-'<.YMI\@-BY+
MMK<^<W^Q=BY=,.=?Y3D<HI,Z4M*2;CQ8S+2&8-74U\=*68D&(TQ#AQT)98:;
M:0E!61&G(=9 .5X+@N8[-S'&M?:^QJYS'-\QN8./XOB^/P7K*YO+FR>3'A5]
M?"CI4X\\\XK_ &DI21J49)(S(+)3TZ>OC*/7IQ;+!MAYE:9#M#9-TUL#8>-Q
M[YVTP# +QZ"B"QC6%0TI1"*7&JVV47%BT2OS*<U^!:XS$8RIM.LI;9QB "NM
M]^' :;Q$Y>W.T\/IW6=&<FK&ZV'BLF)$6BLQ;8,J5\S8^!..H_J>,:+>9^;U
MS1):;*NL4L,DKX;QE=2=8^E#16,@ =Q:"WYM;C%MO#-WZ5RN9ANQ<%LBL:6W
MBDEUAYIUI<6QI[> Z2HMO07=>\Y%FPWTJ9DQG5(47UZDF->8L$?7/[P^+G-N
MBH,0S^_Q_C_R06VQ M-:YA=-U^-9?:)0VVJPU9EUL<:ONH]HZKN:IY#J+N,K
MO;)N4TT4QVFU9CZDMV8Q   :SN;GMIX8\%:RV@['V1 S/:\-F0BOTAK:7 R;
M83]DAI2H\7(X\:2==@,-USM[I%R]$,V^XV&Y"T^,YBLR(&_L7]I7(GV-9JQ+
MV'+9PG4.-63\W7FD<7F2G,6QU9ID1H]Y?S'B9D9EFZJZ0IEVSD-M-MDMU,.-
M#:=<:5;%8CZT-:0R !WKQLXX;:Y9;FPO1&E,:>R;/,VGG'B,]WQZRFK(R3D7
M.39%8K(V:G':" A<B5(7U,D))#:7'EMMKB9TC46:WK_X-ZQ]?W'/%]%Z\)%O
M;(Z7^S=@/PVX=ML?84^,PW=9),90IU4*L9)E$2K@^1WX-;'9:4X\]YI#U,S,
MSJEFV(    $"C[H?.%7O.[5F%L/FN%@?&K%5/L&Z:B8OLJS_ &-:3U):1+>:
M:)ZDCUA]3:9>49'W=[9-&5M.2)1L!F "1-]LAA)Y+[$<CR5R/W,:ZXY;$R%N
M2I*_&S8W&4:_PN.RA:6UH*3(@9++-*5&CN;;<,C/MZ'A?D0L !4D   !H=]_
MW N9R\XC'L[7]*[:[KXQG=9UCD*"UY+'*==SH\0]F8E':;2;LR<W7U,>WA-E
MWNN/UBH[*37+/KE2=)^@5W8N0  "5%Z?_?FUH+&\3XM\U)5O;ZDHFHU'K+>4
M9FQO\CUQ5>991L8V% ;<F6V28'4LN):KI<%IZQIX[:8O@E1/#\'"U=>,<Q-+
MUSL[7.X,1J\^U3G6);&PF[:)VJRK"K^KR6AFEV(6MMFSJ9,J+\ADG")QHU$X
MTH^U:4J^@J2YR  .IMS;XTQQWPR;L+>6SL+U9AL!#JG+S-+Z#2L2GFDDKX-5
M'DNE-N[9[N)+,.&T_+?6I*6VU*41',1,\A#P]FWW&^0;,KLBTEP'_4& X;8-
M2ZC(>1EJQ)HMA9!"<4N/(:U72N>.PU_73(Q&:;B9V7W8\1L1ZM]HG5YQ3VH1
M17GGI+SLB0ZZ_(?=<>??><4Z\\\ZHUNNNNK-2W'7%J,U*,S,S/J8L'C  $U/
M[?OU%3-?,T'/#DQBJXF:6D YO'/7=_#=9EXG463#C*MLY'53&&UL9%=U[IIQ
M]EPC^)!>.<:?.]$7&KO;P@2TQ6D     80\G_8]PGX=%(B;]Y!81BV3QT(7_
M  ^J),K--DJ\R$KBF]@.'1KS)ZV-,[R)N5,C1H9_4S=)*5&4Q$SR&A[>GW4F
MF:-V57<<^,N?[#<2;\=G)MKY52ZTJFW$=2:GQ<>QN+L.UN(+JRZI:?E5+YH,
MC5V*(T#.*3XHU:M-F_<R^Q+,W)#>$5FA]/PC[DQ%XMKZPR6Y:;-1*2N7.V'D
MV65,N2GZEW-U\=LT_P#J^OU.?)!JPAS+W/\ M#SM3JKOF-LR";R>U98;!PO7
M22+JR?[I&OL6QA#"OW"?J@DG]5?^6ONGRU'0]M[$>?EX<TK3FYRTDLV*5HF0
MD\B-M1JUYMU/8XS^5Q<M8KD1UI^AMI:2@_\ 8$Z1[!Q:'S:YFUTIF;7\N>3L
M&;&63D>7#WWM6-*8<(C(G&9#&5H=:61'^U)D8:1[!V3C_LX]B>,O_(KN;W*.
M2YYF7^W(-V9_EC'>P:C0GXN57ES&\*N[\;?9XW/IWI5T(/+'L';-_P"Y7V.9
MIK3-M.["Y#O[(UIL7$;K",OQ?.]=:JO_ ,UH;VL>J9J$Y ]A+>609Z(SYK9E
M1Y[4AF027T+)U"%E'E@:P!D #W*ZQL*>P@VU3.F5=K5S(MC66==*?A6%=80G
MT284Z#-C+:DQ)D22TEQIUM25MK22DF1D1@+*GTV^Q2'[!.+=?9Y9.AHY!:@_
M+,'W95-&TT[;S2AJ+&]F1(C1(0U6[!@0G774H0VVQ;1IS#:"9;94NFT:3]"6
MW$8@         T*?<;Z&+;OKDR/.X,-,B_X];"PO:$9;:5*F+Q^RF.:[RN(T
M:2,OB-0LR:L9!'T(D5A*Z]4D1YTGB*\06H    6*/H%X*EQ)X;5>R<UH55F[
M.395FQLL*?%4Q;X[@!1W3U=A3R'DMOQ%,TDURXELK0V^U.N'([Q&<9OMJO.L
MI;U1@
M                                                 /$\RS)9=CR&
MFI$>0TXR^P\VAUEYEU!H=:=:62D.-.(49*29&1D?0P$+3W%^@^SPZ5E'*/@G
MB,NVPR0JQR+:/'BACG)M,.>6X4F;D6G*>''^19XDLEN.R<?;\DJK4DU0"=AJ
M3%@V5MX2A$J4E2%*0M)I6DS2I*B-*DJ2?125)/H9&1E]2%@_
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MXB;A:VG".8G.I2E"4H0E*4)224I21)2E*2Z)2E)="))$7T(5)5Z?W*&4(O\
MV7VU2EQ*SPC1^J,76DE/*-E<MN_S0FU$Z1(0HT9>2^C?5'11&?XS416T^%$M
M PS !8$_;+8+^EO71<9,Y&['ME\A]D92U*6SVNR*^GH,%P-AEM]4..MV'&GX
MA*-"2<?0AYQWHM*E+;15?XDPD.C   !7G_<G9L65^S&ZHB>4[_#/26I\)-!N
M*648Y\>\V/X4I4HR92HM@>3M+H1FX:NG51F=M/A0T$C, $J'[57"BG\E>4.Q
M?#W'BVC<>PHI'X/W19]GU?>FS]5$Y^_/6Q*^A&7[OZF1].N%^1"<**D@
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MI)UE+I#"ZYW\1I>*]G;,O+ILNV2E"513QV 9][*C5YB[%IZ+2NO)X$)EHK2
M                    .JMVZ2U=R+U=E^F=S8A5YSKK.:MRJR#'[5M1H<0:
MDNQ)\"6TIN94W53,;1)A38RVI4.4TAYE:'$)405ZWM*],>[?7]D%KG^',7&V
M^*T^8A5'LZ)$3(O<%*8XEN/CNVJVO8;;IYK4A7ACV[+95-B1M'W1I+IPF[JV
MB?K0TKC(                ;]/6IZ%N0O,B3CVT-YL7G'WC9*^-8M6]K 3%
MVALFL=;;E,HUYBUI'5^5T]E&6DT7UHTF)V.I=B1[ B6E&%K1'+F)WO'/C5I+
MB;JVDTWH+ :;7^"4G5_X5:VIVQO+=UEAB;DF4W<E3MKDV2V+<9M+\Z8ZZ^IM
MMMLC2TVVVBN9F>,I=ZB       &@K[DW-BQ7UG7=$;_A/9>[-382EON07RC@
M2KK8W@Z*<0:^TL -WHDEG^[Z].A&HLZ?$*\X6H 'V,=HK#*,@HL9J6_-:Y%<
M5E%6,]C[GEL+>:Q7PF_'&9D25]\F0DNC;:UGUZ)2H^A&%OU1T\+'J6GH*U"F
MZZCJZ^G@-J[.Y$*LB,PHJ%>-#;?<EAA)'VI2G_8(B^@XZ7U         %<Q]
MQ#FY9=[2MQ5")"I#.N<)T_A#*B>4\RT;NNJ/-Y4=@S?>;;2Q/S1Y+B$$V27R
M<)2>_N4JZGPH:0!D "3!]K=AAV_-_<V:NH6N+AO&B^KFE))9(:MLLV/KEN(X
MM:7$I/K5TDY)-J2HE&KN^AH+KA?D0GC"I(   #"SG]PIU]SXXSYMH+.C:K+&
M>T60:WS0HY2)F ;*J(THL9RAAOIWR()+DN1+*,DT*EU<J0RE;;BT.MS$Z3J*
MP_D!H/:7&'<&<Z+W-C4C%=B:_MUU-W6NF;L62VMIN767=--[$-VF/W]7(9F0
M);9=DF*^A9=.O0KXG7BATX   #O;2W*#D;QQGNV.AMY;4U&])=)V?'P+.,AQ
MRKME$22(KNEKY[-/>-%V)/LEL/H[D)/IU2DRB8B>8S\I/>[[7\?@HKH'+>W?
MCH-*B<N]4Z'R:<9I9:8+OM,CU;:V;A=C)&9*>,C6:EG^-2E''EJ.'9I[H_:)
MGK,AB\YB[(@HE*[G%876X/K=Y)]C:/ZGDZ[Q/%I$1/1LOHTI!=>I_M4HS>6H
MUZ9[LK8VU;YW*=H9_FVR,G?2:7\CSW*KW,+YY*EJ<4EVWR&?8V#B3<4:C(W#
M^IF?[1D.$@ #LG4.GMF[\V-BNI=/89>9_L/-+-FJQ[&:"*<F9+?</J[)D.*-
M$6MJJ]@E/S)LEQF)"C-K>?<;:0M9)G3B+"#U&>G/7GKXQ>)L_8GY7L#ECE5$
MB-D66);;EX_J^#8M&JQPK6AO,H>2IUMPH]G<K),FQ)!H:3'BK6RY3:VO#P2W
M>C$  !B-SAX<:QYV<=,VX^[/:^+&O64VN'9='BMRK?7V?5;,@\9S2F0MQ@W7
MJU^0MJ5')UHIU<_(B+6A#ZE%,3I.HK'^5G%7<W#3=64Z*WEC+V/9=CCWG@SF
MB<>Q_,<;D//MTV9X?:J;;;N,:NVV%&TZDDN,NH<CR$,R67F6[HF)Y(8Y"0
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M^WU^.H8VG2!9B)2E"4H0E*4)224I21)2E*2Z)2E)="))$7T(4I?H
M
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M9T_56RM783Y.[KW_ * Q?*+WL[/EK[?'_$OKU\#?7N_ICG3M:KOS(2R16D
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MLBKNE1?1XRR;>L,5R:"N9C>65:'%$DY5;+E1R5^$U]Q&161,3R'08D
M    !MGX?>E/GOS"<K;FCU7)U!K.:MEQ>T-W-6.#4DB"LV5JEXWCTB _FN7(
M>C.*5'?@URZYUQ!MKEM'U,L9M$"8#P*]#?#SAD]39SF-?_?)[QK%L36,^V33
M0T8GC-FTG\,G M9&_9T=0\P\E+K$RR>M[.,^@G(\F/\ S"KFTSRY);OAB
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MQ96"2,T&@BIM.L_0EN5&(
M
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M&V+ET9_8.Q&9A(\;LVNR_-'[NTQYV07\]NK5!C_7HEM)?083:92S[$
M      "/C[M/59R@]E&6<?9ND\XTABV+:>QW8,6PB;6R;8%)82+_ #JRQ5V3
M)J8^):XSJ"[#_+L1BI6MQR.[WIZ=JDDDRSK:*\QHU_U6SV _]L'#K^V!NO\
M\/@R\\?2C0_U6SV _P#;!PZ_M@;K_P##X'GCZ31F9Z]?MZN77%GF;H7D'MK9
M7&J\P#5656&3W=5@69;4LLMEOMXO?0J--1!O=/8G4R%-Y#,B+>)^>PDHZ7#+
MR*(FEQ-XF-!,,%:0        !!KV]]M/[!=H[8V?LUW;?$!AW8NQ,USMQB1G
M^XBD,N9=DMGD"VGRB<>6HA/-JL.BO$E+?<1]I$70A;%XB$.N_P#5;/8#_P!L
M'#K^V!NO_P /@>>/I-#_ %6SV _]L'#K^V!NO_P^!YX^DT23?2YZZMI>N/0&
MT-=;HR'6F3Y[G^X9.:MVFK+/(KJA1B,?"\1HJ2!-L<KPK![G\WCW,&U<6R4=
MV*VR\TIMSO<>2G"TZSP2W%C$      !UOMG3NJ][X/;:UW+K[$MFX'=DG\QQ
M;,Z2#>U+KS27$QIS#$UIPX-I!-U2HTM@VI49P^]IQ"R(PY"-%RK^UXT?FTNQ
MR7B1N*_TI82%ORFM<[&B2MBX 3JU+-JOILF;EPLZQFO:)2?WDU61O'VF7]$7
M;G%Y\4:-'>V_MY?9YK"1*_(]48=N:IBK61W6J-EXM(;=;2M2&W6://)6!Y:_
MY2(C[6ZY:TD?U(NA],XO486Y#ZP?8MC#BF[+A%R?DJ1(.,9X]IG.<N;-PD&Y
MW)=Q2GNFEQ^TOZ:1FUW?3NZF1"?-'M'QJ[UO>PBTE(AQN#?+=IYPEJ2NQX[[
M9J(I$V@UJ[Y]MBD*"T9DG\)*<(U']"ZF9$'FCVCO+"O2S[1,]<912\/-BUWF
M2A1+S6TP?73;:5HD.$;RL_RO&O$I*(JNY)]%DHT)Z=SC9*CS5&PO2_VP?-W-
MI$.3N+8VE='TCJB*=';MK?9V:Q"-)*[F*+&X%?B,Q*>ID?7(FCZE]",OJ(\\
M&C?IQ(^WCX'<<)-;DVQZBXY29]!['DV&W&H2->Q)J6TH6[6:JJ^M#+C+Z*,F
M;U^^)"E=R5$I*33C-YE+>K65E;2UT&GIJ^#4U-7$CP*VKK(D>!75T&(TEB+"
M@PHK;4:)$C,H)#;;:4H0DB(B(B& ]X        !\#*<4Q?.<>M\1S7&Z#,,4
MR"&Y77V,933UV08]=U[W0W8%O2VT>76V4-WM+N:>:6A73ZD CR\L_MJ>'6ZY
MMIE/'W)\HXMY=8/.RUTM/$+/]3.2'4J<=\&%75G67U#\B3T[45]VS BH4:6H
M7:2$ISB\QS-&@W<_VV_L=UL_.=U_3ZLWY4,=78KV ;"K<;NGXI'U4J32;01@
MS+4QM!&I3$>7,[NG1M3BC)(R\\(8#Y7ZI/9'ACTIBWX4\AIBX9&IY6*:[N<\
M9629+D0_BR,':R)B<?E:,R)A3AFT9.%^[4E1Y>:OM'#:_P!<'L(LI;4*/P;Y
M<MO/>3L78<==MU,1/C:6ZKRV%IB4.!'ZH;,D^1Q/>KHE/51D1O-'M&1&O?2'
M[1MD.QRJN)F88[%>2EQV=L+(L#UVU$95X>KLB%F654]PM2/.GJTS&=?^BNB#
M[%]L>:HVI<?_ +67?60R8-ER6Y!:YUG3&XAZ3C>JZVYV3ECT9)H)R#)MKR-A
M6-44YW\71YC\Z9;+M,TK,U(1$WCP-$BOA]Z:>!7#%^JR'!M4(V+LZI>;EQ-M
M;G?AYYF<&:R9JCS<?B.5U?AN(3(JEJ\<FHJH4SM5T<><Z$983:92VH#$
M     $$G+_MD/8=F.69/E]CM_AT5AE617623R_B%NE72;>64FSE%W(X\,I5^
M_E*^I(21_P"P7[!;YX^E&CCO^JV>P'_M@X=?VP-U_P#A\#SQ])H?ZK9[ ?\
MM@X=?VP-U_\ A\#SQ])HE3^I;A-G/ /AW1:#V;<81?Y^G.\ZS3)K;7<^ZM,5
ME/Y'9,M57P9^18QB%S(>8QVLAMO^:$CM=0I*%+;2DQA:=9U2V8C$
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MR5454]OJ1FD8VG2!9%BE(
M
M
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MN7
M
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M-]"D*ZTVG64MJXQ
M
M
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M-ITJ+,X4I
M
M                                             1!/NPK.8UC_  8I
MD,]U?/N.1=G)D='?W4RIA:3BP6>XE>$O.S=2%=%$:C\?X3(B5ULQ^*)0U!8
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M<N9C:TN-.1*E4=U)%*08QO.D:>(L2!2D
M
M
M
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MHEMLSNT_PO'UKO/#0A-P%:0
M
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MG9V45U>=K3MRV2[)-;AD"+&IHJTGV.MP3?Z$MY?6FTZRELA&(
M
M
M
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M%2I9_7"J#"J*)(=0EPFT_3/WTMFI!FK\?:9$2R.S&B4+(6#E>#8+F>S<OQ[
M-=XK?YOF^663%/C6*8O5S+J_O+.29^&%6UD!I^7*>-*349)29)0E2E=$I,R"
MRS]0? Z5Z_\ A[C>M,L*"]M_.[>3L[<<B \S,BPLNO(%?!AXG"L&D$4N#AN/
MUD6$I:%N,.STRGV5&V\0IM.LI;2!B
M
M
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MLFQO%8:K')\AH\<KT(?<5.OK:!3PTMQFC?DN*DV$B.P2(["36LS5T0@NI]"
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M$W5Z]K$$\@FI)X>F,]D#JFU*7%EPZ\G$]DDNN%YTC06!8J2
M
M
M
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M54L2_>KY%NRPG&,AHVWTS7JJ.I1O$X:?&7:9=3ZS$S'(8N_YD#U7?XH&'?\
MXY[7_P#GX3YK>T9>Z X7\4>+!2G./>@-8ZJL)\1,"QR#&<9A(RVS@(4E:8%G
MF,Y,S*K*"EQ)+)E^8XV2^JNWN,S.)F9YC)P0
M
M
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M!IU-L4]>\:4+75UD;N(E=11:=9U2SO$
M
M
M
M
M
M
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MHVQLQQV:A,[%ZO$F'U+J84QIFQD6IMRU(CLPV?FUWMX0)E0K2
M
M
M
M
M
M
M                         ZCWM_U4YA_U1_\ NQ7_ %[?]5/\]/\ SP__
M *9_L_[?03 A7<K?X/?G>0?Q+_U;?M_,K'N_@M_?U?J7L[IO3\Y_O2?WWY]X
M>[Y?;^\^9^W][V"R/V4--.T/X">6?^E/[QSL\,CX_P#"_P#SE/B[_F.^/X'\
M:/W_ )O#T\?ROW?A[>_][W#*-?I_<&/W_P!RO_\ #O\ _P! !Q^D<TPO^%WS
M'OSS^]I\'?#[/UI_?B?#[?*OS>'^'?\ PAV=G3S>3\79T\7XNH<?I&S'0O\
M>S?*A?I__,<?GWF;\O\ 'K_.Y?%[_DS_ (OS?XG?_P!MO#XNO=X?W?C\7R/W
MG01Q^G]P2]/6!V?I6;XO\U!X_!.\?^;1^1^3=GRV>S\\^7_5?F[?_KGE_>?)
MZ=WUZBNW[*6VL8@
(        _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
